Introduction {#s1}
============

The many cells of the brain are produced through the highly regulated repeated divisions of a small number of neural stem cells (NSCs). NSCs grow and divide rapidly in order to supply the cells of the developing brain, but must be restrained to prevent tumour formation. Individual NSCs produce characteristic lineages of progeny cells ([@bib35]; [@bib50]), which vary in number suggesting differences in division and growth rates during development. However, the mechanisms differentially regulating the growth and division of individual NSCs are currently unknown.

Many of the processes and factors regulating neurogenesis are conserved between mammals and insects, making *Drosophila* an excellent model system to study NSC regulation ([@bib33]). During *Drosophila* neurogenesis, NSCs, also known as neuroblasts (NBs), divide asymmetrically, budding-off a small progeny cell, the ganglion mother cell (GMC), which divides into neurons that progress through differentiation. During larval neurogenesis, the NB divides on average once every 80 min ([@bib31]) and regrows between divisions to replace its lost volume, maintaining the proliferative potential of the cell ([@bib33]). However, average measurements of growth and division mask considerable heterogeneity between the behaviour of individual NBs in the brain over developmental time. Individual NBs produce unique lineages of neurons ([@bib57]), with characteristically different clone sizes ([@bib76]). Individual NBs also have differing division frequencies ([@bib28]) and terminate division at different times (NB decommissioning) ([@bib74]). This individual control ensures that the appropriate number of each neuron type is produced in the correct location during the construction of the brain. Systemic signals such as insulin and ecdysone signalling drive NB growth and division, with a particularly strong influence at the transitions between developmental stages ([@bib11]; [@bib25]; [@bib32]; [@bib60]; [@bib62]; [@bib65]; [@bib66]). However, the reproducible heterogeneity between individual NBs implies the existence of an unknown local or cell-intrinsic signal, acting in addition to the systemic signals to determine the proliferation of each NB.

The temporal regulation of NB proliferation and progeny fate has been well studied in the embryo and larva, and many key factors have been identified ([@bib20]; [@bib42]; [@bib51]; [@bib61]). The developmental progression of larval NBs is characterised by the levels of two conserved RNA-binding proteins (RBPs), IGF2 mRNA-binding protein (Imp/IGF2BP2) and Syncrip (Syp/hnRNPQ) ([@bib43]). Imp and Syp negatively regulate each other and are expressed in opposing temporal gradients through larval brain development ([@bib43]): Imp level in the NB declines through larval development while Syp level correspondingly increases. Imp and Syp play numerous key roles in larval neurogenesis. The levels of Imp and Syp are known to determine the different types of neuron produced by the NBs over time, through post-transcriptional regulation of the transcription factor (TF) *chinmo* ([@bib43]; [@bib60]). The loss of Syp results in an enlarged central brain, in part due to an increase in NB proliferation rate ([@bib28]). In pupal NBs, declining Imp expression allows NB shrinkage and Syp promotes NB termination ([@bib74]). Temporal regulation of the Imp/Syp gradients depends on the upstream temporal patterning system ([@bib54]; [@bib60]; [@bib66]). The timing and rates of change of these RBP levels differ substantially between classes of NB, and to a lesser degree between NBs of the same class ([@bib43]; [@bib66]; [@bib74]). However, it is unknown if the intrinsic levels of Imp and Syp in each NB play a role in controlling the growth and division rates of individual NBs during their main proliferative window in the larva.

Imp and Syp are RBPs and can modify the protein complement of a cell via post-transcriptional modulation of mRNA localisation, stability and translation rates ([@bib9]; [@bib26]; [@bib30]; [@bib47]; [@bib48]; [@bib49]; [@bib53]). Cell growth and proliferation are classically thought to be regulated at the level of transcription by pro-proliferative TFs. Various signalling pathways converge to promote cell growth and proliferation through transcriptional upregulation of the conserved TF and proto-oncogene, Myc ([@bib15]; [@bib17]; [@bib41]; [@bib68]). Myc interacts with a binding partner, Max, to exert widespread transcriptional effects, binding upwards of 2000 genes in *Drosophila* ([@bib56]). In *Drosophila,* Myc is best known for its role in promoting cell growth through increased ribosome biogenesis ([@bib27]), and also accelerates progression through the G1 phase of the cell cycle in the developing wing, though this does not affect overall cell cycle length ([@bib34]). It is unclear whether the transcriptional activation of pro-proliferative TFs, such as Myc and its downstream targets, is overlaid by post-transcriptional regulatory mechanisms executed by RBPs, such as Imp and Syp, which could increase the precision and flexibility of the system.

Here, we examine the role of the Imp/Syp temporal gradient in regulating NB size and division during larval neurogenesis. We show that the upregulation of Imp increases NB division and size, while Syp influences these processes indirectly via its negative regulation of Imp. We use a genome-wide approach to determine the mRNA targets bound by Imp in the brain and identify *myc* mRNA among the top 15 targets of Imp. Single molecule fluorescent in situ hybridisation (smFISH) shows that *myc* mRNA is stabilised by Imp, leading to increased Myc protein levels, NB growth and proliferation. We compare NB types with different Imp levels and find that low Imp levels result in unstable *myc* mRNA, which restrains NB growth and division. Finally, at an earlier time point, when Imp expression is heterogeneous between individual NBs, we find that higher Imp correlates with increased *myc* mRNA half-life. We propose a model in which Imp post-transcriptionally regulates *myc* mRNA stability to fine-tune individual NB size and division rate in their appropriate developmental context.

Results {#s2}
=======

Imp promotes type I NB growth and division {#s2-1}
------------------------------------------

To investigate the roles of the opposing Imp and Syp gradients in the NB, we used RNAi knockdown to manipulate the level of these RBPs ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We studied the type I NBs, the most numerous NB type in the brain, which are also very convenient to analyse, as they have a simple division hierarchy with each asymmetric division producing a GMC that divides only once more to produce two neurons or glia ([@bib4]; [@bib7]; [@bib8]). In the wandering L3 stage (wL3) brains all type I NBs express high levels of Syp and low of Imp ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). We depleted Syp or Imp from the NBs with *Syp* knockdown and *Imp* knockdown RNAi constructs using the GAL4-UAS system, driven by *insc-GAL4* ([@bib6]). In NBs Imp and Syp negatively regulate each other and therefore the *Syp* knockdown results in Imp upregulation ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}) ([@bib43]). We distinguished between direct effects of Syp depletion and indirect effects due to upregulated Imp expression by analysing *Imp Syp* double knockdown mutants ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}) ([@bib74]). We also examined Imp overexpression brains, but the UAS overexpression construct only produces a very limited upregulation of Imp in the type I NB at the wL3 stage ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}), as previously observed ([@bib43]; [@bib74]). Therefore we primarily use the *Syp* knockdown to upregulate Imp.

We first examined the roles that Imp and Syp play in influencing type I NB size. Our results show that higher Imp promotes larger size of type I NBs at wL3, and Syp acts indirectly through its negative regulation of Imp. Imp-depleted NBs are almost half the size of *wild type* NBs and NBs that overexpress Imp are 1.4-fold larger in midpoint area ([Figure 1A,A'](#fig1){ref-type="fig"}, Materials and methods). Syp-depleted NBs are 1.5-fold larger than *wild type*. We tested whether this effect is direct or indirect by studying the size of NBs in the *Imp Syp* double knockdown. Our results show that Imp depletion suppresses the increase in NB size observed in *Syp* knockdown mutants, which indicates that Syp only plays an indirect role in type I NB size, through its repression of Imp.

![Elevated Imp levels increase NB proliferation and size.\
(**A**) Phalloidin was used to stain F-actin, marking the perimeter of each type I NB in the central brain (the largest cells, identified with Deadpan (Dpn) immunofluorescence (IF)). The area of each NB was measured at its largest point, and the average NB size per brain is plotted in (**A'**). NBs with diffuse Dpn (indicating nuclear envelope breakdown during mitosis) were excluded. (**B**) Larval brains were cultivated ex vivo with 25 μM EdU for four hours. All cells that underwent DNA synthesis in S phase are labelled with EdU. Dpn IF labels type I NBs. The number of progeny produced by each NB in the central brain was compared in *wild type, Imp* RNAi, *Syp* RNAi, double *Imp Syp* RNAi and Imp overexpression (OE) brains. The average number of progeny per NB in each brain is plotted in (**B'**). In **A'**) and **B'**), significance was calculated using a one-way ANOVA and Dunnett's multiple comparisons test, with comparison to *wild type*. \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. Each grey point represents one wL3 brain and for each genotype at least seven brains were measured, from three experimental replicates.](elife-51529-fig1){#fig1}

NB size is affected by both cell growth and division rate so we then tested whether NB division rate is also sensitive to Imp levels. We incubated ex vivo explanted brains in 5-ethynyl-2'-deoxyuridine (EdU)-containing media for four hours to label the progeny cells produced during this time (see Materials and methods). The number of labelled progeny was decreased by more than half in the *Imp* RNAi brains compared to *wild type* ([Figure 1B,B'](#fig1){ref-type="fig"}), which suggests that the decreased NB size in the *Imp* knockdown is not due to an increased division rate. The number of progeny was increased 1.4-fold in the Imp overexpressing brains and increased 1.6-fold in the *Syp* RNAi brains, in which Imp is strongly upregulated, compared to *wild type.* This phenotype is consistent with the increased proliferation rate previously observed in *Syp* knockdown brains with ex vivo culture and live imaging ([@bib28]). However, the increased proliferation was lost in the *Imp Syp* double knockdown brains. These results, together with our previous findings that Imp overexpression prevents NB shrinkage in the pupa and extends NB lifespan ([@bib74]), suggest that low levels of Imp in the late larval NBs restrains NB growth and division, ensuring the brain growth is limited appropriately during its development.

Imp binds hundreds of mRNA targets in the brain, including *myc* {#s2-2}
----------------------------------------------------------------

Imp is an RBP, so is likely to exert its function in the NB through regulation of the RNA metabolism of its key target mRNA transcripts. In an effort to identify strong candidate targets, we identified the transcripts bound by Imp in the brain. To achieve this aim we performed Imp RNA immunoprecipitation and sequencing (RIPseq) in larval brain lysates (see Materials and methods). We identified 318 mRNA targets that were significantly enriched in the Imp pulldown compared to input brain RNAseq (using the thresholds DESeq2.padj \< 0.01 and DESeq2.log2FoldChange \> 2) ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}). The list of targets includes known Imp targets such as *chickadee* (target rank: 37) ([@bib49]), as well as mRNAs that have previously been shown to be regulated by Imp. Imp binds *syp* mRNA (target rank: 103), which indicates a post-transcriptional mechanism for the previously observed negative regulation of Syp by Imp ([@bib43]). Another Imp target is *chinmo* (target rank: 55), which is known to be post-transcriptionally regulated by Imp to determine the progeny fate of NBs in the mushroom body (MB), the centre for memory and learning. Chinmo is also regulated by Imp in type II NBs ([@bib43]; [@bib60]; [@bib66]) and during NB self renewal ([@bib18]; [@bib54]). Imp binds a number of long non-coding RNAs, including *CR43283/cherub* (target rank: 5). *cherub* is also a binding target of Syp and facilitates Syp asymmetric segregation during type II NB division ([@bib36]). The large number of Imp targets identified by RIPseq indicates that Imp has a broad range of roles in the developing brain. Imp has been shown to regulate mRNA localisation, stability, and translation ([@bib16]). Our results suggest that examining the Imp targets will provide further insight into the role of Imp in neurogenesis and the critical importance of post-transcriptional regulation.

To identify the key candidate mRNA targets responsible for the Imp NB size and division phenotypes, we examined the gene ontology (GO) annotations of the top 40 Imp targets ([Figure 2A](#fig2){ref-type="fig"}). We searched for genes annotated to play a role in cell growth, cell size, cell cycle and neural development, as well as regulatory genes with RNA-binding or DNA-binding function ([Figure 2B](#fig2){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}). We identified *myc* (target rank: 13) as the top candidate that could explain the Imp phenotype, based on these GO categories. As discussed in the introduction, *myc* is a master transcription factor regulator of growth and division in diverse model systems. In *Drosophila* it is primarily known as a driver of cell growth ([@bib27]), and is a determinant of self renewal in the type II NB ([@bib6]). We also identified a second member of the Myc transcriptional network, *mnt*, as an mRNA target bound by Imp (target rank: 36). Mnt competes with Myc for binding to Max, and promotes opposed transcriptional effects ([@bib44]; [@bib56]). We first focussed on *myc,* and later investigated *mnt. myc* is the 13th most enriched target of Imp and is a very promising candidate as a direct mediator of the Imp phenotype in NBs.

![Imp RNA targets in the *D. melanogaster* wL3 brain.\
(**A**) Ranked top 40 Imp RIPseq targets relative to baseline RNA expression as measured by RNAseq. Non-coding RNAs that overlap other genes are excluded. (**B**) Genes in panel A mapped to gene ontology (GO) terms related to cellular growth and division, neural development, and regulatory functions RNA- and DNA-binding. Each dot indicates the gene is annotated to one or more GO terms in that category. The colour of the dots reflects the total number of GO categories each gene maps to, out of the seven investigated.](elife-51529-fig2){#fig2}

To further examine the interaction between Imp and *myc* mRNA, we reanalysed a previously published dataset of Imp iCLIP (individual nucleotide resolution cross-linking and immunoprecipitation) performed in S2 cells ([@bib29]). The iCLIP data shows that Imp directly binds the *myc* transcript ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}), which supports our identification of *myc* mRNA as an Imp target in the brain. The iCLIP experiment identifies Imp binding sites primarily in the *myc* untranslated regions (UTRs) and binding signal is enriched in the extended 3' UTR of the longer mRNA isoform. In our brain Imp RIPseq dataset, we also see reads throughout the extended 3' UTR, suggesting that Imp binds to the long *myc* mRNA isoform ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}). Notably, the full *myc* 3' UTR extension is expressed in the brain ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}) but it is truncated early in the S2 cells ([Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}), so the fully extended transcript in the brain may contain additional Imp binding sites. The results in S2 cells support our identification of *myc* mRNA as a target of Imp in the brain, highlighting the hypothesis that Imp is a key regulator of *myc* in the NB.

Myc expression is regulated by Imp levels {#s2-3}
-----------------------------------------

To test the hypothesis that Myc protein levels are regulated by Imp, we used antibody staining in *wild type* and knockdown type I NB lineages. We found that Imp is required to maintain correct Myc levels in the NB. We observed Myc protein expression in type I NBs, but not in the surrounding GMCs or neurons ([Figure 3A](#fig3){ref-type="fig"}). Myc protein level was increased more than 2-fold in the *Syp* RNAi NBs compared to *wild type* ([Figure 3B](#fig3){ref-type="fig"}, quantitated in 3C), while this effect was lost in the double *Imp Syp* depleted NBs. Directly overexpressing Imp resulted in a small increase in Myc protein level (1.2-fold increase on *wild type* level) ([Figure 3C](#fig3){ref-type="fig"}). The effect of Imp overexpression on Myc protein level is smaller than that in *Syp* knockdown NBs as the overexpression construct produces a smaller upregulation of Imp ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). *Imp* knockdown produced a small decrease in Myc protein level ([Figure 3C](#fig3){ref-type="fig"}), as expected because Imp levels are already very low in *wild type* type I NBs. These data indicate that Imp upregulation increases Myc protein level in the NB, while Syp's effect on Myc is indirect, as it requires Imp.

![Imp upregulates Myc protein expression, which in turn determines NB division rate and size.\
(**A**) Antibody staining against Myc protein, with NBs labelled with Dpn. Myc protein is restricted to the NB in the *wild type* type I lineage. (**B**) In the *Syp* knockdown, Myc protein is increased in the NB, but this increase is lost in the *Imp Syp* double knockdown. The average Myc IF signal in NBs per brain is quantitated in **C. D**) Myc overexpression increases NB size, measured as NB area at the widest point. *Myc* RNAi results in a non-significant decrease in NB size. *Myc Syp* double knockdown reverses the phenotype of *Syp* single knockdown, resulting in small NBs compared to *wild type*. (**E**) EdU staining to count progeny produced in a 4 hr incubation shows that overexpression of Myc increases NB proliferation. Significance was calculated using a one-way ANOVA and Dunnett's multiple comparisons test, with comparison to *wild type*. ns non significant, \*p\<0.05, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 Each grey point represents one wL3 brain and for each genotype at least eight brains were measured, from three experimental replicates.](elife-51529-fig3){#fig3}

We next examined the effect of Imp and Syp on Mnt, the antagonist of Myc, also identified as an Imp target. Using antibody staining, we found that Mnt protein is expressed in the type I NB, as well as in the progeny cells of the lineage ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). However, knockdowns of *Imp* and *Syp* have no effect on the levels of Mnt protein. Therefore, we conclude that Mnt is not likely to be a key target responsible for the NB growth and division phenotype of Imp.

We then asked whether the upregulation of Myc by Imp could be responsible for the phenotype of increased type I NB growth and division. We overexpressed the Myc open reading frame (ORF) in type I NBs ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}, Materials and methods) and found a significant 1.3-fold increase in NB size ([Figure 3D](#fig3){ref-type="fig"}). *Myc* knockdown produced a small and not significant decrease in NB size. We used a *Myc Syp* double knockdown to confirm that upregulated Myc is responsible for the increased size of *Syp* knockdown NBs (in which Imp is upregulated). We found that the increased NB size in the *Syp* knockdown is lost in the *Myc Syp* double knockdown brains (*Myc*\_*Syp* RNAi NBs are 0.7x the size of *wild type*), supporting the hypothesis that Imp regulates NB size through upregulation of Myc.

We tested the effect of Myc overexpression on type I NB division rate, and observed an increased division rate in the Myc OE compared to *wild type* (*Myc OE*: 4.04 EdU-labelled progeny per NB, [Figure 3E](#fig3){ref-type="fig"}). The observed increase in division rate is a surprising result as previous work in the wing disc showed that Myc overexpression increased cell size without affecting division rate ([@bib34]), highlighting that Myc could regulate cell size and division rate in distinct ways in different tissue contexts. In the NB, we find that increased Myc protein levels can explain the increased size and division rate that occur in response to overexpressing Imp. However, Imp levels are very low in wL3 *wild type* type I NBs ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), which may limit Myc protein expression and restrain NB growth and division.

Imp stabilises *myc* mRNA {#s2-4}
-------------------------

In order to further characterise the regulation of *myc* mRNA by Imp, we visualised *myc* mRNA transcripts using smFISH in type I NBs ([@bib75]). The two annotated RNA isoforms of *myc* are identical except that the longer isoform includes a 3' UTR extension of 5.7 kb ([Figure 4A](#fig4){ref-type="fig"}) (FlyBase, [@bib69]). This additional UTR sequence potentially includes substantial regulatory sequence, including multiple binding sites for Imp according to iCLIP in S2 cells ([@bib29]) ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}), which could allow differential regulation of the two isoforms. smFISH probes against the *myc* intron and common exon show *myc* transcription and mature *myc* transcripts in the type I NB ([Figure 4A,B](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}, [Supplementary file 2](#supp2){ref-type="supplementary-material"}). Co-staining with the common exon probe and a long-UTR-specific probe, showed that all cytoplasmic transcripts in the type I NB are positive for both probes ([Figure 4A,C](#fig4){ref-type="fig"}). This result shows that the extended UTR isoform of *myc* (*myc^long^*) is the predominant isoform expressed in the NB. Therefore, we used probes specifically against the *myc^long^* isoform for the following quantitative experiments.

![Imp stabilises *myc* mRNA.\
(**A**) We designed smFISH probes targeting the common exon (spanning the exon junction due to insufficiently long single exons), the intron, and the extended 3' UTR. (**B**) smFISH against the *myc* exon and the intron shows that *myc* is transcribed in type I NBs. (**C**) smFISH using probes against the common exon and the 3' UTR extension of *myc* shows that the long isoform of *myc* is expressed in the type I NBs. (**D**) *myc* transcript number is increased in the *Syp* knockdown. Z projection of 5 z planes. (**E**) The number of *myc^long^* transcripts was counted in individual NBs. The transcript number increased in the *Syp* RNAi but was unchanged in the double *Imp* and *Syp* RNAi. (**F**) The number of nascent transcripts was calculated using the integrated intensity from the transcription foci spot. The number of nascent transcripts was not significantly changed between genotypes. The counts of nascent and mature transcripts were then used to calculate *myc^long^* half-life and transcription rate ([@bib3]). (**G**) The *myc^long^* transcription rate is reduced in the *Imp Syp* double knockdown. (**H**) *myc^long^* mRNA is stabilised in the *Syp* RNAi but the half-life is unchanged in the *Imp Syp* double knockdown. Significance calculated by ANOVA and Dunnett's multiple comparisons test, with comparison to *wild type*. ns = non significant, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. error bars represent s.e.m. Each grey point represents one NB and for each genotype wL3 brains were analysed from three experimental replicates.](elife-51529-fig4){#fig4}

Imp binds to *myc* mRNA and could upregulate Myc protein either through increasing *myc* mRNA levels or increasing Myc translation. To distinguish between these possibilities, we stained brains with *myc^long^*-specific smFISH probes and quantitated the RNA expression in individual NBs within the mixed-cell tissue ([Figure 4---figure supplement 1B,C](#fig4s1){ref-type="fig"}, Materials and methods, [@bib52]). We measured the effects of *Imp* knockdown, Imp upregulation using the *Syp* knockdown, and suppression in the *Imp Syp* double knockdown. Due to the minimal upregulation of Imp with the Imp overexpression construct ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) and correspondingly small upregulation of Myc protein ([Figure 3C](#fig3){ref-type="fig"}), we did not quantitate the *myc* mRNA expression in the Imp overexpression brains ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). The number of *myc^long^* transcripts per NB is significantly reduced in the *Imp* knockdown, and is significantly increased in the *Syp* knockdown ([Figure 4D,E](#fig4){ref-type="fig"}). The transcript number is similar to *wild type* levels in the *Imp Syp* double knockdown, showing that Imp, rather than Syp, is the primary regulator of the number of *myc^long^* transcripts observed in the NB. We interpret our results as showing that the increase in *myc* transcript number observed when Imp is upregulated causes the observed increase in Myc protein level. In contrast, Imp is unlikely to upregulate Myc protein levels primarily through an increase in *myc* translation efficiency, although the data does not exclude the possibility that this mechanism makes a minor contribution to Myc protein upregulation.

The number of mature transcripts is affected by both transcription rate and mRNA stability. In order to distinguish between a role for Imp in regulating *myc* transcription rate or *myc* transcript stability, we used smFISH measurements to estimate the transcription rate and mRNA half-life of *myc^long^* in each NB ([@bib3]). We used the average intensity of a single transcript to calculate the number of nascent transcripts at the transcription foci, which indicates the relative transcription rate ([@bib52], Materials and methods). We found that while the number of nascent transcripts is not significantly changed in the *Imp* knockdown or the *Syp* knockdown, it is significantly reduced in the *Imp Syp* double knockdown ([Figure 4F](#fig4){ref-type="fig"}). We used this measurement to estimate the transcription rate and showed that *myc^long^* transcription is unchanged in the single knockdowns, but is significantly reduced in the *Imp Syp* double knockdown ([Figure 4G](#fig4){ref-type="fig"}, Materials and methods, \[[@bib3]\]). This change in *myc* transcription in *Imp Syp* double knockdown NBs is unexpected, and may be an indirect effect through other transcription factors that Imp and Syp regulate, or a feedback loop of Myc autoregulation.

To determine the post-transcriptional role of Imp in regulating *myc* transcript level we calculated the *myc* mRNA half-life, allowing direct comparison between genotypes despite differing transcription rates (Materials and methods, \[[@bib3]\]). We found that the half-life of *myc^long^* is not significantly changed in the *Imp* knockdown, but is significantly increased in the *Syp* knockdown, in which Imp is upregulated (*wild type* = 18.6 mins, *Syp* RNAi = 43.2 mins) ([Figure 4H](#fig4){ref-type="fig"}). This increase in *myc^long^* mRNA half-life is suppressed in *Imp Syp* double knockdown NBs, in which there is no significant difference compared to *wild type*. It is not surprising that the *Imp* knockdown has no effect on *myc* mRNA half-life when compared to *wild type* NBs, because Imp levels are very low in *wild type* type I NBs at the wL3 stage. We find that Imp's main direct role is to promote *myc^long^* mRNA stability and this results in upregulation of Myc protein, which promotes NB growth and division.

To characterise the regulation of Myc in other cells in the type I NB lineage, we used smFISH to observe *myc* transcription and cytoplasmic transcripts in the whole lineage ([Figure 4B,C](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). We found that while *myc* is transcribed and transcripts are present in all cells in the lineage, Myc protein is limited to the NB only ([Figure 3A](#fig3){ref-type="fig"}), suggesting that *myc* transcripts are translationally repressed in the progeny GMCs and neurons. The repression of Myc protein expression in the progeny cells was unaffected by manipulation of Imp and Syp levels, driven by *insc-GAL4* ([Figure 3B](#fig3){ref-type="fig"}), suggesting that these two RBPs are not responsible for translational regulation of *myc*. While in the type II NB lineage, Brat is thought to translationally repress *myc* in progeny cells ([@bib6]), it is not known to act in the type I lineage. We conclude that Myc is regulated in the NB lineages by mRNA stability through Imp and by translation, perhaps through a different RBP.

High Imp stabilises *myc* mRNA in mushroom body NBs {#s2-5}
---------------------------------------------------

The gradient of Imp level decline with developmental age is different between different NB types ([@bib43]; [@bib66]; [@bib74]). Therefore, we used smFISH to explore whether *myc* mRNA is also differentially stable in distinct NB types. Imp level declines more slowly in MB NBs compared to the rest of the type I NBs in the central brain and higher Imp expression remains in the MB NBs at wL3 ([@bib43]; [@bib74]). In each NB, we used smFISH to measure *myc^long^* transcription, *myc^long^* mRNA half-life and *myc^long^* transcript number as well as NB size and Imp protein level ([Figure 5A](#fig5){ref-type="fig"}). We identified MB NBs by their elevated Imp expression ([Figure 5A,B](#fig5){ref-type="fig"}). We found that MB NBs are 1.5-fold larger than type I NBs ([Figure 5C](#fig5){ref-type="fig"}). The *myc* mRNA half-life is 2.5-fold higher in the MB NBs (type I NBs = 18.79 mins, MB NBs, 51.34 mins) ([Figure 5D](#fig5){ref-type="fig"}, Materials and methods), while *myc* transcription rate is slightly reduced in the MB NBs compared to the type I NBs ([Figure 5E](#fig5){ref-type="fig"}). Plotting these variables together shows clear differences between the type I NBs and MB NBs. While type I NBs show low Imp, unstable *myc* mRNA and small NB size, the MB NBs have higher Imp, more stable *myc* mRNA and larger NB size ([Figure 5F](#fig5){ref-type="fig"}). These results support our earlier finding that higher Imp promotes *myc* mRNA stability and NB growth and indicates that Imp is a key regulator of differences between different classes of NBs.

![Higher Imp level in MB NBs leads to more stable *myc* mRNA.\
(**A**) wL3 brains expressing Imp::GFP and stained with *myc^long^* smFISH probes and phalloidin were used to measure Imp level, NB size, *myc^long^* transcription rate and half-life in individual NBs. MB NBs are identified by their higher Imp expression compared to type I NBs. (**B--D**) Each grey point represents one NB and for each NB type, brains were analysed from three experimental replicates. (**B**) MB NBs express higher Imp than type I NBs. The average intensity of cytoplasmic Imp signal is shown in arbitrary fluorescent units. (**C**) MB NBs are significantly larger than type I NBs, comparing NB area at the largest plane. (**D**) *myc* mRNA half-life is increased in MB NBs compared to type I NBs. (**E**) *myc* transcription rate is slightly lower in MB NBs than in type I NBs. (**F**) Plotting multiple measurements for each NB (Imp level against *myc* mRNA half-life, with NB size indicated by the colour scale) shows the differences between type I NBs (diamond point - low Imp, low *myc* mRNA stability, small) and MB NBs (circle point - high Imp, high *myc* mRNA stability, large). Imp level correlates with *myc* half-life. (**G--H**) Each grey point represents one brain and for each NB type, brains were analysed from three experimental replicates. (**G**) Myc protein is increased in MB NBs compared to type I NBs. (**H**) MB NBs produce more progeny in a four hour EdU incubation compared to type I NBs. Significance for each measurement was calculated using unpaired t-test, except for **G**) which uses a paired t-test. \*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](elife-51529-fig5){#fig5}

We also measured Myc protein levels and NB division rates in MB NBs and type I NBs, although these could not be multiplexed into the same images as the smFISH measurements. We found that Myc protein level is 1.4-fold higher in MB NBs compared to type I NBs ([Figure 5G](#fig5){ref-type="fig"}). Finally, we measured NB division rate by incubation with EdU, which showed that MB NBs have a faster division rate than type I NBs ([Figure 5H](#fig5){ref-type="fig"}). Collectively, these results suggest that the higher level of Imp maintained into the late L3 stage in the MB NBs increases *myc* mRNA stability, causing increased Myc protein levels and increased NB growth and division relative to type I NBs at the same stage.

Imp regulates *myc* mRNA stability throughout neuroblast development {#s2-6}
--------------------------------------------------------------------

Imp levels decline in NBs as larval development progresses ([@bib43]) so we next asked what role Imp plays in *myc* regulation in earlier larval neurogenesis. We studied brains at 72 hr after larval hatching (ALH) when the Imp protein level in the NB is higher than at the later wL3 stage and there is substantial heterogeneity in Imp expression level between the individual NBs ([Figure 6A](#fig6){ref-type="fig"}). We first compared the average populations of 72 hr ALH NBs to wL3 NBs. Imp protein levels were measured from endogenous GFP-tagged Imp and found to be significantly increased in the 72 hr ALH NBs compared to wL3, as expected ([Figure 6B](#fig6){ref-type="fig"}). We then measured NB size and found that NBs are significantly larger at 72 hr ALH ([Figure 6C](#fig6){ref-type="fig"}). smFISH quantitation of *myc^long^* transcription and half-life at 72 hr ALH showed that *myc^long^* half-life is increased at 72 hr ALH ([Figure 6D](#fig6){ref-type="fig"}), but there was no significant difference in *myc^long^* transcription rate ([Figure 6E](#fig6){ref-type="fig"}). To validate the role of Imp in early larval neurogenesis, we measured NB size in Imp-depleted early NBs. NBs were much smaller in the *Imp* knockdown than in *Imp::GFP* (*wild type*) brains at 72 hr ALH ([Figure 6F](#fig6){ref-type="fig"}). This data supports the model that the decline in Imp levels during larval development reduces *myc* mRNA stability, restraining NB growth and division at the end of the larval stage.

![Imp stabilises *myc* mRNA throughout larval development.\
(**A**) Imp level (measured with endogenous Imp::GFP) is higher in NBs at 72 hr ALH compared to the wL3 stage, and is more variable between different type I NBs. Imp is very highly expressed in the progeny cells so the image is contrasted to show the Imp levels in the NBs. (**B**) Imp level quantitated in 72 hr ALH and wL3 type I NBs. (**C**) NBs are larger at 72 hr ALH compared to wL3. (**D**) *myc* mRNA half-life is longer in 72 hr ALH NBs compared to wL3. (**E**) The transcription rate of *myc* is not significantly different between 72 hr and wL3 NBs. Significance was calculated using unpaired t test. ns = not significant, \*\*p\<0.01, \*\*\*\*p\<0.0001 **F** Measuring the size of type I NBs at 72 hr ALH shows *wild type* (*imp::GFP*) NBs are larger than *Imp* knockdown NBs. (**G**) In individual NBs at 72 hr ALH, increased Imp expression correlates with increased *myc* mRNA half-life. Imp level is normalised to the highest expressing NB from each imaging session. Each grey point represents one NB and for each stage, brains were analysed from three experimental replicates.](elife-51529-fig6){#fig6}

Pooled averages hide the substantial variation in between individual NBs at 72 hr ALH so we asked whether the Imp level in each NB determines *myc^long^* half-life. We used a correlation matrix to examine the relationships between the variables measured in each individual NB at 72 hr ALH ([Figure 6G](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) and found that Imp level correlates with *myc^long^* half-life (r = 0.344, p\<0.01) in individual NBs. We also found a significant correlation between *myc^long^* transcript number and NB size (r = 0.281, p\<0.05), which supports the hypothesis that Myc is a significant regulator of NB size at this stage. However, we found no significant correlation between Imp levels and *myc^long^* transcript numbers or NB size. The *myc* transcript number is controlled on multiple levels through both transcriptional and post-transcriptional mechanisms, and transcriptional activation of *myc* is a downstream consequence of many signalling pathways in the brain. Imp regulates *myc* mRNA stability to modify the final number of transcripts in each cell and as Imp levels decline through development *myc* mRNA stability also decreases. These results support the hypothesis that intrinsic Imp levels provide a mechanism to fine-tune the amount of Myc protein produced in each NB, allowing NB growth and division to be determined in each NB independently throughout its lifespan.

Discussion {#s3}
==========

Each NSC produces a characteristic number of progeny to build a functional brain with the correct number of neurons of each type in each sub-region ([@bib76]). However, how division rates are individually controlled through development is poorly understood. Here, we show that the temporally regulated RBPs Syp and Imp regulate NB division rate and size. Imp directly promotes NB growth and division through stabilising the mRNA of one of its key targets, *myc*, while Syp acts indirectly by negatively regulating Imp. By stabilising *myc* mRNA, Imp increases Myc protein expression and drives NB growth and proliferation. Imp levels decline to low levels in type I NBs by the final wandering larval stage and we find that this results in low *myc* mRNA stability and low Myc protein levels. We show that Imp heterogeneity between NBs in earlier larval development (at 72 hr ALH), correlates with *myc* mRNA stability in individual NBs. Therefore, we suggest a model in which post-transcriptional regulation of *myc* mRNA stability by Imp provides a cell-intrinsic mechanism to fine-tune the growth and division rate of individual NBs, superimposed on the known extrinsic drivers of these processes ([Figure 7](#fig7){ref-type="fig"}).

![Imp stabilises *myc* mRNA to promote NB growth and division.\
(**A**) Myc drives growth and proliferation in NBs. We show that Myc level is regulated by intrinsic levels of Imp through increased *myc* mRNA half-life. Syp negatively regulates Imp to affect Myc levels indirectly. In our model, the post-transcriptional regulation of *myc* by Imp overlays potential extrinsic growth signals (labelled with a '?'), activating *myc* transcription. Multiple layers of regulation control growth and proliferation in each NB through development. (**B**) In early larval brains, Imp level is high, *myc* mRNA is relatively more stable and NBs are large. In individual NBs Imp level correlates with *myc* mRNA half-life. At the wandering larval stage Imp level is low in type I NBs, *myc* mRNA is unstable and NBs are small and divide slowly. This is in contrast to the MB NBs which maintain higher Imp levels, have more stable *myc* mRNA, and are larger and faster dividing.](elife-51529-fig7){#fig7}

Post-transcriptional regulation of *myc* by Imp modulates NB growth and division {#s3-1}
--------------------------------------------------------------------------------

Myc is known to promote stem cell character and must be switched off in progeny cells to allow correct differentiation ([@bib6]; [@bib24]). We found that Myc overexpression increases both type I NB size and division rate, which is a very interesting result since Myc is best known to drive cell growth through activation of ribosome biogenesis ([@bib27]). Myc also promotes a shortened G1 phase in the wing disc, but this does not increase division rate as the G2 phase is proportionately lengthened ([@bib34]). In the NB, the increased division rate we observe with Myc overexpression could be the result of a direct effect of Myc driving cell cycle progression, which would be mechanistically different from the cells of the wing disc. Alternatively, division rate may be increased indirectly as a result of the larger cell size. Further experiments will be required to uncover the precise mechanism of Myc action in the NB.

Our discovery of Imp-dependent modulation of Myc levels adds another dimension of regulation allowing cell-intrinsic modulation of NB growth and division tailored to individual NBs. It has been shown that Brat, an RBP, translationally represses Myc in type II NB progeny cells (intermediate neural progenitors) to prevent formation of ectopic NBs ([@bib4]; [@bib6]; [@bib7]; [@bib8]). Together these findings emphasise the importance of the complex network of RBPs that play crucial post-transcriptional roles to control growth and division in individual NBs and their progeny in brain development.

Our work also suggests a new potential mechanism by which NB growth and division is restrained toward the end of the stem cell lifespan, in preparation for the terminal division in the pupa. The intrinsic regulation of *myc* mRNA stability by Imp could explain why NBs are insensitive to the general growth signalling pathways at their late stages ([@bib32]). Homem et al., show that activation or inhibition of signalling through insulin-like peptides or their effector FOXO, has no effect on NB shrinkage or termination. Our results demonstrate that in the late larval NBs, there is insufficient Imp to stabilise *myc* mRNA, so that upregulation of *myc* transcription would still lead to low levels of Myc protein.

Regulated Imp levels control *myc* mRNA stability in individual NBs and NB types {#s3-2}
--------------------------------------------------------------------------------

MB NBs are the longest lived NBs in the larval brain and their growth and division only finally slows at about 72 hr after pupal formation ([@bib63]), 24 hr after the termination of the other type I NBs ([@bib74]). It was previously shown that NB decommissioning is initiated through a metabolic response to ecdysone signalling, via Mediator ([@bib32]). Elevated Imp level inhibits Mediator in the MB NBs to extend their lifespan by preventing NB shrinkage ([@bib74]). However, [@bib74], found that inhibition of the Mediator complex only partially explained the lack of cell shrinkage in the long-lived MB NBs, suggesting that other targets of Imp also play a role in MB NBs. Imp stabilisation of *myc* mRNA might additionally promote NB growth to contribute to extending the MB NB proliferative lifespan. In contrast, Imp levels decline faster in the other type I NBs, which would restrain their growth and division in preparation for their earlier decommissioning.

We also examined the role of Imp earlier in larval development, at 72 hr ALH when Imp levels are higher and heterogeneous between individual NBs. Type I NBs at 72 hr ALH have higher *myc* mRNA stability and increased cell size compared to type I NBs at wL3. Our measurements of multiple variables in single cells allowed us to examine the function of Imp expression heterogeneity between individual NBs. We found that Imp levels correlate with *myc* mRNA stability in individual NBs at 72 hr ALH, providing a cell intrinsic mechanism to modulate NB growth and division. However, Imp levels do not correlate with NB size, unlike at the later wL3 stage. In the early larva, Imp and Myc levels are rapidly changing so a snapshot measurement of NB size may not be a suitable proxy for cell growth at each time point. Resolving this issue will require more sophisticated methods for long-term imaging of live whole brains that allow direct measurement of the growth and division rates of each NB at the same time as the Imp and Myc levels.

We have identified a mechanism of cell-intrinsic regulation of individual NB division and growth, which we suggest plays a key role in ensuring the correct number of progeny is produced in each lineage to build the correct sub-regions and circuits in the brain. This intrinsic regulatory mechanism must be integrated with extrinsic growth signals in the brain to determine the growth and division of each stem cell throughout development. Systemic insulin and ecdysone signalling are known to promote the timing of developmental switches in NBs, at the exit from quiescence after larval hatching and the decommissioning of the NB in the pupa. In the final stages of larval development, brain growth is also driven locally to protect it from nutrient restriction, in a process called brain sparing, by which Jelly-Belly expressed by the glial niche bypasses the insulin signalling pathway ([@bib12]). It is plausible that this local extrinsic regulation might also be specific to individual NBs, for example through controlled expression level of Jelly-Belly in each glial niche. Future experiments will determine the interplay between the intrinsic regulation of *myc* stability by Imp that we have shown here, and other extrinsic systemic and local regulators of NB growth and division.

Declining Imp may restrain proliferation in diverse stem cell populations and systems {#s3-3}
-------------------------------------------------------------------------------------

*c-myc,* the mammalian homologue of *Drosophila myc*, is best known for its role in cancers, and so its regulation has been studied extensively (reviewed in [@bib13]; [@bib23]). It is therefore interesting to consider to what extent the mechanism we have uncovered is conserved between *c-myc* and *Drosophila myc*. The mammalian homologue of Imp, IGF2BP1, binds to *c-myc* mRNA and regulates its stability. However, IGF2BP binds to *c-myc* mRNA in the coding sequence, whereas Imp binds to *myc* UTRs in *Drosophila*. IGF2BP1 is known to stabilise *c-myc* transcripts by blocking translation-coupled decay ([@bib5]; [@bib21]; [@bib40]; [@bib71]), but in *Drosophila,* Imp's exact mechanism of stabilisation is not yet known. Nevertheless, the similarity of the two cases suggests that Imp regulation of *myc* stability might play a conserved role, coordinating stem cell growth and division with developmental progression.

The activity of stem cells in every context must be precisely restrained to prevent uncontrolled proliferation, and produce the correct numbers of each cell type to build the organ. We have discovered an important new regulatory mechanism, that Imp acts through *myc* mRNA stability to modulate cell growth and division appropriately in each stem cell and each stage of development. During development, lengthening of the G1 phase to extend the cell cycle length of NSCs is correlated with a switch from expansion to differentiation in the mouse ventricular zone ([@bib67]). It has been proposed that Myc is a critical link between cell cycle length and pluripotency ([@bib64]). In parallel, Imp expression levels have been shown to occur in declining temporal gradients in diverse stem cells including the *Drosophila* testis ([@bib70]) and, in vertebrates, mouse foetal NSCs ([@bib55]). These diverse studies support our proposal of a new general principal that Imp temporal gradients limit stem cell proliferative potential towards the end of their developmental lifespan, by reducing *myc* mRNA stability and leading to low Myc protein level. Future experiments in a wide range of other organs and systems will now be required to test our model, and to examine the extent of Imp expression heterogeneity in other stem cell systems.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                         Designation                                                  Source or reference                 Identifiers                                                          Additional\
  or resource                                                                                                                                                                                                 information
  ------------------------------------- ------------------------------------------------------------ ----------------------------------- -------------------------------------------------------------------- ---------------------------------------------------------------------
  Gene (*Drosophila melanogaster*)      Syncrip (Syp)                                                                                    FBgn0038826                                                          

  Gene (*Drosophila melanogaster*)      IGF-II mRNA-binding protein (Imp)                                                                FBgn0285926                                                          

  Gene (*Drosophila melanogaster*)      Myc                                                                                              FBgn0262656                                                          

  Gene (*Drosophila melanogaster*)      Mnt                                                                                              FBgn0023215                                                          

  Genetic reagent (*D. melanogaster*)   *wild type*\                                                 Bloomington                                                                                              
                                        OregonR                                                                                                                                                               

  Genetic reagent (*D. melanogaster*)   *Syp* RNAi                                                   VDRC                                VDRC 33011                                                           *;P(GD9477)v33011*

  Genetic reagent (*D. melanogaster*)   *Imp* RNAi line                                              Bloomington                         BL 34977                                                             *y(1) sc\[\*\] v(1)*; *P{y\[+t7.7\] v\[+t1.8\]=TRiP.HMS01168}attP2*

  Genetic reagent (*D. melanogaster*)   Imp OE line\                                                 [@bib43]                                                                                                 
                                        UAS-Imp-RM-FLAG                                                                                                                                                       

  Genetic reagent (*D. melanogaster*)   Myc OE line                                                  FLY-ORF collection                  F001801                                                              *M{UAS-Myc.ORF.3xHA.GW}*

  Genetic reagent (*D. melanogaster*)   *Myc* RNAi                                                   Bloomington                         BL 54154                                                             *y(1) v(1); P{y\[+t7.7\] v\[+t1.8\]=TRiP.HMC03189}attP40*

  Genetic reagent (*D. melanogaster*)   Imp::GFP                                                     [@bib70]                                                                                                 *Imp\[CB04573\]*

  Genetic reagent (*D. melanogaster*)   insc-GAL4                                                    [@bib6]                                                                                                  

  Antibody                              α-Syncrip (guinea pig,\                                      [@bib48]                                                                                                 1:2000 WB,1:500 IF
                                        polyclonal)                                                                                                                                                           

  Antibody                              α-GFP (rat, monoclonal)                                      Chromotek                           3H9 RRID:[AB_10773374](https://scicrunch.org/resolver/AB_10773374)   1:1000 WB

  Antibody                              α-αTubulin (mouse, monoclonal)                               Sigma                                                                                                    1:500 WB

  Antibody                              α-Imp (rabbit, polyclonal)                                   Gift from P. M. Macdonald                                                                                1:600 IF

  Antibody                              α-Deadpan (rat, monoclonal)                                  abcam                               11D1BC7\                                                             1:200 IF
                                                                                                                                         RRID:[AB_2687586](https://scicrunch.org/resolver/AB_2687586)         

  Antibody                              α-Myc (mouse, monoclonal)                                    Gift from R. N. Eisenman and DSHB   P4C4-B10                                                             1:100 IF

  Antibody                              α-Mnt (mouse, monoclonal)                                    Gift from R. N. Eisenman                                                                                 1:100 IF

  Commercial assay, kit                 GFP-trap agarose beads                                       Chromotek                           gta-20                                                               

  Commercial assay, kit                 Stellaris DNA probes                                         Stellaris                                                                                                

  Commercial assay, kit                 Phalloidin                                                   Sigma                                                                                                    

  Commercial assay, kit                 RNAspin Mini kit                                             GE Healthcare                                                                                            

  Commercial assay, kit                 NEBNext Poly(A) mRNA Magnetic Isolation Module               NEB                                                                                                      

  Commercial assay, kit                 Ion Total RNA-Seq Kit v2 for Whole Transcriptome Libraries   Life Technologies                                                                                        

  Commercial assay, kit                 Agilent High Sensitivity DNA Kit                             Agilent                                                                                                  

  Commercial assay, kit                 Click-iT EdU Alexa Fluor 488/594 Imaging Kit                 Invitrogen                                                                                               

  Software, algorithm                   GraphPad Prism version 7                                     GraphPad Software                                                                                        

  Software, algorithm                   ImageJ version 2.0.0                                         Fiji                                                                                                     

  Software, algorithm                   FISHquant                                                    [@bib52]                                                                                                 

  Software, algorithm                   Transquant                                                   [@bib3]                                                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Experimental model and subject details {#s4-1}
--------------------------------------

*Drosophila melanogaster* fly stocks were kept at 18°C, but transferred to 25°C for crosses and experimental use. OregonR was the *wild type* strain. Flies were raised on standard cornmeal-agar medium.

Method details {#s4-2}
--------------

### RNA extraction {#s4-2-1}

Third instar larval brains were dissected in Schneider's insect medium and then flash frozen in liquid nitrogen. Brains were homogenised using a pestle in IP buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% NP-40, 10% glycerol, one mini tablet of Complete EDTA-free protease inhibitor and 2 μl RNAse inhibitor (RNAsin Plus RNase Inhibitor, Promega). RNA was extracted using the RNASpin Mini kit (GE Healthcare) according to manufacturer's instructions.

Reverse transcription and quantitative PCR cDNA was produced from extracted RNA using RevertAid Premium Reverse Transcriptase (Thermo Fisher Scientific) according to manufacturer's instructions with the addition of 1 μl RNAse inhibitor (RNAsin Plus RNase Inhibitor, Promega).

Real time quantitative PCR was performed using primers specific to a transcript of interest, and where possible spanning an exon junction. qPCR was performed using SYBR Green Master Mix with the CFX96 Touch Real-Time PCR Detection System (BioRad). Cycle threshold (C(T)) values were calculated from the BioRad CFX software using a second differential maximum method. Input samples were used for a dilution series and the percentage input of each gene was calculated in the IP samples as a measure of pulldown. For primer sequences see [Table 1](#table1){ref-type="table"}.

###### qPCR primers.

  Gene       Forward                   Reverse
  ---------- ------------------------- -------------------------
  *rp49*     GCTAAGCTGTCGCACAAA        TCCGGTGGGCAGCATGTG
  *pros*     TATGCACGACAAGCTGTCACC     CGACCACGAAGCGGAAATTC
  *chic*     CTGCATGAAGACAACACAAGC     CAAGTTTCTCTACCACGGAAGC
  *syp*      TATGTGCGAAATCTTACCCAGGA   CGTTCCACTTTTCCGTATTGCTC
  *myc*      CGGCAGCGATAGCATAAAAT      ACCTCGTCGGTAAGACTGTGA
  *Eip93F*   cgatgtgaagtccgtcagag      gatttccgggcatctagctt
  *mamo*     ccatcagagcccataaggtg      caaaacggacgtccttcaat

### RNA immunoprecipitation {#s4-2-2}

Wandering larval brains were dissected and homogenised in IP buffer (see RNA extraction). Input samples were taken. Each experiment was done in triplicate. 200 *Imp::GFP* brains were used per IP for sequencing. The lysate was incubated with GFP-Trap agarose beads (Chromotek) at 4°C for two hours and the unbound supernatant was collected. Beads were washed in cold IP buffer for 4x quick washes. The bound material was eluted by incubation for 30 min at 65°C in Elution buffer (50 mM Tris HCl (pH 8), 10 mM EDTA, 1.3% SDS, protease inhibitor, RNase inhibitor). The elution step was repeated and the supernatants were pooled. RNA was extracted for IP samples and inputs and used for RT-qPCR or sequencing libraries.

### Western blot {#s4-2-3}

Proteins were separated by SDS-PAGE on a 4--12% Novex gradient gel then transferred to nitrocellulose membrane with the Trans-Blot Turbo Transfer System (BioRad). Membranes were blocked in 50% Odyssey Blocking Buffer in 0.3% PBST (1x PBS with 0.3% Tween) for 1 hr at RT. The membrane was incubated with primary antibody overnight at 4°C. After rinsing, the membrane was incubated with fluorescently labelled secondary antibodies for LICOR (1:2000) for 2 hr at RT. Membranes were washed in 0.3% PBST and imaged with the LI-COR Odyssey.

### polyA selection {#s4-2-4}

For RNA sequencing, after RNA extraction mRNA was enriched through polyA selection with the NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB) according to manufacturer's instructions. Briefly RNA sample was added to washed beads with Binding buffer. Samples were incubated at 65°C for 5 min and then cooled to 4°C for RNA binding. Beads were washed in Wash Buffer and RNA was eluted at 80°C for 2 min. Binding, washing and elution steps were repeated to improve purification with final elution in 17 μl of Tris Buffer.

### RNA sequencing {#s4-2-5}

Three biological replicates (n = 3) were produced for each sample (whole transcriptome/input or immunoprecipitation). Poly(A) enriched RNA was then used for library production using the Ion Total RNA-Seq Kit v2 for Whole Transcriptome Libraries (Life Technologies). Libraries were produced according to the Ion Total RNA-Seq Kit v2 protocol. Following quality control steps, adaptors were hybridised to the RNA fragments and RT reaction was performed followed by cDNA amplification with Ion Xpress RNA Barcode primers. Prior to sequencing, quality of cDNA libraries were assessed using Agilent High Sensitivity DNA Kit with the Agilent 2100 Bioanalyser. Libraries were pooled to a total concentration of 100 pM, with three samples multiplexed per chip. Sequencing was performed on an in house Ion Proton Sequencer, using the Ion PI IC 200 Kit (Life Technologies). Ion PI chips were prepared following manufacturer's instructions and loaded using the Ion Chef System.

Staining and imaging {#s4-3}
--------------------

### Antibody staining for immunofluorescence (IF) in larval brains {#s4-3-1}

Larval brains were carefully dissected in Schneider's medium and collected into 0.2 ml PCR tubes. Samples were rinsed once with 0.3% PBSTX (0.3% Triton-X in 1x PBS) and then fixed in 4% paraformaldehyde (PFA) (4% PFA in 0.3% PSTX) for 25 min (for wL3) or 15 min (for 72 hr ALH) at room temperature (RT). Samples were rinsed briefly 3x in 0.3% PBSTX, and then washed 3 × 15 min in 0.3% PBSTX at RT. Blocking was for 1 hr at RT in Blocking Buffer (1% bovine serum albumin (BSA) in 0.3% PBSTX). Samples were incubated with primary antibody diluted in Blocking Buffer overnight at 4°C on a rocker (Note: we were unable to optimise Myc antibody staining in 72 hr ALH brains). Samples were rinsed and then washed 3 × 15 min in Blocking Buffer at RT. Alexa Fluor secondary antibody (Thermofisher) was added at 1:200 in Blocking Buffer and samples were incubated for 1 hr at RT in the dark. Samples were rinsed briefly and then washed 3 × 15 min in 0.3% PBSTX at RT. For nuclear staining, DAPI (4',6-diamidino-2-phenylindole) was included at 1:500 in the second 15 min wash. Brains were mounted in VECTASHIELD anti-fade mounting medium (Vector Labs). Slides were either imaged immediately or stored at −20°C.

Single molecule RNA fluorescent in situ hybridisation (smFISH) for larval brains {#s4-4}
--------------------------------------------------------------------------------

smFISH probes were designed using the Stellaris Probe Designer version 4.2. The sequences against which the probes were designed are shown in [Supplementary file 2](#supp2){ref-type="supplementary-material"}. Stellaris DNA probes were gently resuspended in 95 μl fresh TE buffer and 5 ul RNAse inhibitor (RNAsin Plus RNase Inhibitor, Promega), and frozen at −80°C in 10 μl aliquots. Dissected brains from male larvae were rinsed once with 0.3% PBSTX and then fixed in 4% PFA (in 0.3% PSTX) for 25 min (for wL3) or 15 min (for 72 hr ALH) at RT. Samples were rinsed briefly and then washed 3 × 15 min in 0.3% PBSTX at RT. Samples were washed for 5 min in Wash Buffer (10% deionised formamide (stored at −80°C) and 2x SSC in DEPC water) and then incubated with 250 nM Stellaris DNA probes in Hybridisation Buffer (10% deionised formamide, 2x SSC and 5% dextran sulphate in DEPC water) overnight at 37°C on a rocker. Samples were rinsed briefly 3x in Wash Buffer, and then washed 3 × 15 min in Wash Buffer at 37°C. For nuclear staining DAPI (4',6-diamidino-2-phenylindole) was included at 1:500 in the second wash. Brains were mounted in VECTASHIELD anti-fade mounting medium (Vector Labs). Slides were either imaged immediately or stored at −20°C.

Additional stains {#s4-5}
-----------------

DAPI was used to stain nuclei, and was added at 1:500 in one of the final wash steps before mounting. Phalloidin was used to label F-actin and was added in one of the final wash steps and incubated for 1 hr at 37°C. Fluorescein 488 phalloidin was used at 5 μl per 100 μl, 647 Phalloidin was used at 2.5 μl per 100 μl.

5-ethynyl-2'deoxyuridine (EdU) labelling {#s4-6}
----------------------------------------

Brains were dissected in Schneider's medium and then transferred to Brain Culture Medium (80% Schneider's medium, 20% fetal bovine serum (Gibco ThermoFisher), 0.1 mg/ml insulin (Sigma)) with 25 μM EdU for 4 hr. Brains were then washed with Schneider's medium and fixed for 25 min in 4% PFA in 0.3% PBSTX at RT. The samples were rinsed and then washed 3 × 15 min in 0.3% PBSTX at RT before blocking for 1 hr at RT in Blocking Buffer. Samples were incubated with anti-Dpn antibody in Blocking Buffer overnight at 4°C. The following day, samples were washed in Blocking Buffer and then incubated with Alexa Fluor secondary antibody (Thermofisher) at 1:200 in Blocking Buffer and samples were incubated for 1 hr at RT in the dark. Samples were washed 3 × 15 min in 0.3% PBSTX at RT and then fixed in 1% PFA in 0.3% PBSTX at RT for 15 min. Samples were washed and then incubated in Blocking Buffer for 1 hr. The Click-iT reaction was carried out with the Click-iT EdU Alexa Fluor 488 Imaging Kit (Invitrogen) following manufacturer's instructions for 30 min at RT. Samples were washed in 0.3% PBST with 5 mM EDTA, once including DAPI, and then mounted in VECTASHIELD anti-fade mounting medium (Vector Labs). Samples were imaged on the same day.

Image acquisition {#s4-7}
-----------------

An inverted Olympus FV3000 Laser Scanning Microscope was used for fixed imaging of larval brains. Images were acquired using 60x/1.30 NA Si UApoN objective. For smFISH quantitation images, pixel size was 74 nm in x and y, and 200 nm in z.

Quantification and statistical analysis {#s4-8}
---------------------------------------

### Image analysis {#s4-8-1}

#### Replicates {#s4-8-1-1}

For all imaging experiments, staining and imaging was performed in three technical replicates (i.e. staining on three independent days). For each replicate the number of brains analysed ranged from 1 to 5 depending on availability of larvae. These are biological replicates. In [Figures 1](#fig1){ref-type="fig"}, [3](#fig3){ref-type="fig"} and [5G--H](#fig5){ref-type="fig"}, the individual replicates are shown on all plots as individual points. In [Figures 5B--D](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}, the individual NBs measured are shown as individual points on the plots.

#### Measuring NB size {#s4-8-1-2}

We measured all type I NBs in the central brain on the ventral side. We used phalloidin staining to mark the NB cell boundary and the area at the widest z plane was manually measured using ImageJ. NBs undergoing mitosis were excluded. They were identified using Dpn staining, which is weak throughout the cell when the nuclear envelope has broken down during mitosis. In [Figure 1](#fig1){ref-type="fig"} the average NB size per brain is plotted.

#### Measuring proliferation rates {#s4-8-1-3}

We measured all type I NBs in the central brain on the ventral side. Proliferation rate was measured with EdU labelling of progeny cells. The number of EdU +ve progeny per NB (labelled with Dpn) were counted manually. In [Figure 1](#fig1){ref-type="fig"} the average number of progeny per NB in each brain is plotted.

#### NB segmentation {#s4-8-1-4}

Using ImageJ, single NBs were cropped and substacks were made to span the depth of each NB. The phalloidin staining was used to create a mask with the FIJI plugin MorphoLibJ, using the morphological segmentation feature ([@bib39]). NBs undergoing mitosis (condensed chromatin in the DAPI channel) were excluded.

#### smFISH {#s4-8-1-5}

After segmentation as above, transcripts outside the NB boundary were removed. FishQuant ([@bib52]) was used in batch mode to count spots and calculate nascent transcripts using the integrated intensity calculation. In brief, an outline was produced for each NB, identifying the transcription focus (note that as *myc* is on the X chromosome, only male larvae were dissected so there was one transcription focus per NB). Transcription foci were easily identified as the largest spot in the nucleus, with relatively more signal from the more 5' exon probe compared to the 3' UTR probe. A single NB was analysed to set up the detection settings which were then applied in the batch mode of all NBs from each technical replicate. The filters were modified manually to optimise transcript detection, and then an average transcript was calculated from the entire batch and used to calculate the nascent transcript number.

We applied the method established by [@bib3] to convert transcript counts to rates of transcription and mRNA decay. Simply, the nascent transcript number can be used to estimate the transcription rate in each cell, accounting for the position of the probe along the transcript, and an estimated rate of transcriptional elongation. The rate of elongation (v) was estimated at 1.5 kb per minute, based on a variety of methods in different *Drosophila* tissues, which gave measurements from 1.1 to 1.5 kb/min ([@bib2]). A probe library weighting factor was calculated using the TransQuant software to account for the position of the probe set along the gene ([@bib3]). For *myc long* smFISH probes, this factor was 0.15264. Assuming a steady state, where transcription equals mRNA degradation, the estimated transcription rate can then be used to calculate an estimate of mRNA half-life in each cell.

Transcription and decay rates were calculated using the equations below. Decay rates were then converted to half-lives.

1.  Transcription rate (mRNA/hr) = ((nascent transcript number/weighting factor) x elongation rate)/gene length

2.  Decay rate (per hour) = (chromosome fraction x transcription rate x number of chromosome copies)/transcripts in the cell

3.  Half-life (mins) = (ln2/decay rate) x 60

The calculation ([@bib3]) helps to unpick the differences in regulation of transcription or mRNA decay between different genotypes or cell types. However, the assumptions required for the method should be carefully considered in the interpretation of the results. The transcription rate calculation assumes a constant estimated transcription elongation rate without pauses or pulsing. The equations are based on a steady state but, while we excluded NBs undergoing mitosis, a dividing cell like the NB is unlikely to reach a true steady state.

#### Statistical analysis {#s4-8-1-6}

Statistical analysis was performed using Prism (GraphPad Software). For image analysis (smFISH and phenotypic analysis) involving three or more comparison groups (genotypes), one-way ANOVA was used to identify difference between the results of different phenotypes and the *wild type* value. Dunnett's multiple comparison test was then used to calculate significance values of each comparison. This applies to [Figures 1](#fig1){ref-type="fig"}, [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}.

For analysis involving only two comparison groups, unpaired t-tests was used ([Figures 5B--D,H](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). For [Figure 5G,a](#fig5){ref-type="fig"} paired-t-test was used to compare the intensity of Myc protein directly between NB types in the same brains.

In [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} and [Figure 6G](#fig6){ref-type="fig"} a correlation matrix was produced, computing r for every pair of Y values with Pearson correlation coefficients.

The qPCR data ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}) was analysed with a comparison for each gene between the test and control pulldowns. The significance was calculated using t-tests with correction for multiple comparisons with the False Discovery Rate method, using an allowance of 5%.

Bioinformatics methods {#s4-9}
----------------------

### Analysis of RNAseq and RIPseq {#s4-9-1}

Reads from three Imp RIPseq libraries and three RNAseq libraries were mapped to the *D. melanogaster* genome (BDGP6.22.97) downloaded from ENSEMBL using the STAR aligner (2.5.3a) ([@bib19]). The aligned reads were then assigned to genes using htseq-count (0.11.2) ([@bib1]). Imp RIPseq enrichment over baseline RNA expression (RNAseq) was calculated from gene counts after library size correction, and genes were ranked according to this ratio. We additionally used DESeq2 (1.24.0) ([@bib45]) to determine statistically significant difference between the RIPseq and RNAseq. Genes with very low abundance (those with total count of less than 10 across 3 RNAseq libraries) were ignored from ranking. Non-coding RNAs that overlap other genes were flagged up and not considered for [Figure 2](#fig2){ref-type="fig"}. This data is available in a tabular format in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. To capture gene ontology (GO) terms linked to cell growth, neural development, and key regulatory processes, we extracted all GO terms using GO.db (3.8.2) ([@bib10]) and defined the following categories: cell growth (all GO terms that contain word 'cell growth'), cell size ('cell size'), cell division ('cell division'), cell cycle ('cell cycle'), neural development ('nervous system development', 'neurogenesis'), RNA binding ('RNA binding'), DNA binding ('DNA binding'). The GO terms falling under these categories are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Gene-to-GO term mapping was extracted from Biomart using the R package biomaRt (2.40.4) ([@bib22]). The data was analysed in R with the help of the tidyverse suite of packages (1.2.1) ([@bib73]). R libraries rtracklayer (1.44.3) ([@bib37]) and GenomicRanges (1.36.0) ([@bib38]) were used to extract information from the annotation (.gtf) file and determine gene lengths and overlaps. The plots shown in [Figure 2](#fig2){ref-type="fig"} were made using ggplot2 (3.2.1) ([@bib72]). Further details of the analysis and code are available in [Source code 1](#scode1){ref-type="supplementary-material"}.

The [@bib29] S2 *wild type* RNAseq (SRX751581, SRX751582) and Imp RIPseq (SRX751579, SRX751580) datasets were downloaded from the Short Read Archive (SRA) using SRA toolkit (2.9.3) (SRA Toolkit Development Team, <http://ncbi.github.io/sra-tools/>). The reads were mapped to *D. melanogaster* genome (BDGP6.22.97) using the STAR (2.5.3a). Read counts per gene were calculated using HTSeq-count (0.11.2). The [@bib29] Imp iCLIP-seq (SRX751573, SRX751574) and PAR-iCLIP-seq (SRX751575, SRX751576) datasets were downloaded from SRA. Illumina sequencing adapters were trimmed off using cutadapt (1.10) ([@bib46]) and the first five bases (corresponding to molecular barcodes) were removed from sequence and appended to read name. The reads were then mapped to the *D. melanogaster* genome (BDGP6.22.97) using STAR (2.5.3a). *xlsites* from the iCount pipeline ([@bib14]) was used to determine the number of unique crosslinked sites (unique cDNA molecules) for any given position. iCount *peaks* was then used to call significant peaks and iCount *cluster* to cluster significant peaks. To make the gene track plots for myc ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), brain and S2 RNAseq were converted to strand-specific bedgraphs using bedtools (v2.28.0) ([@bib59]). The visualisation was done with Bioconductor package Sushi (1.22.0) ([@bib58]). For the S2 iCLIP-seq, (confident) peaks and corresponding clusters are shown. Only one, representative replicate for each data type is shown.

Data and code availability {#s4-10}
--------------------------

The presented RNA sequencing data has been deposited with Gene Expression Omnibus (GEO), with accession number GSE140704. Further details of the analysis and code are available in [Source code 1](#scode1){ref-type="supplementary-material"}.
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###### Analysis of Imp targets in the *D. melanogaster* larval brain.

Details and code used for the bioinformatic analysis of the Imp RIPseq and RNAseq data presented in [Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.

###### Imp targets and GO terms used for categorisation.

Table of Imp RIPseq targets: including read counts from three Imp RIPseq libraries and three RNAseq libraries, differential expression and GO analysis. GO terms falling under the following categories are listed: cell growth, cell size, cell division, cell cycle, neural development, RNA binding, DNA binding.

###### Stellaris Probes.
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The presented RNA sequencing data has been deposited with Gene Expression Omnibus (GEO), with accession number GSE140704.

The following dataset was generated:

SamuelsTJJärvelinAIDavisI2019Imp/IGF2BP levels modulate individual neural stem cell growth and division through myc mRNA stabilityNCBI Gene Expression OmnibusGSE140704

The following previously published dataset was used:

HansenHTRasmussenSHAdolphSAPlassMKroghASanfordJNielsenFCChristiansenJ2015Drosophila Imp iCLIP identifies an RNA assemblage co-ordinating F-actin formationNCBI Gene Expression OmnibusGSE62997
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The Imp and Syp RNA binding proteins have been shown to play important roles in patterning the divisions of neuroblasts in *Drosophila* (and in vertebrates). This work demonstrates that one of the targets of Imp is the gene Myc, which thus explains why Imp needs to be down-regulated at the end of neuroblast lives in order to terminate them. Therefore, the temporal and spatial regulation of Myc controlled by Imp determines neuroblast growth and rate of division. The authors' utilization of sophisticated mRNA detection allowed them to quantify mRNA in neuroblasts, and to understand how temporal patterning of neuroblasts regulates their proliferation. This will provide further support for the critical role of Imp (and Syp) in neuroblast division and the identification of further targets will likely also allow the authors to understand how these genes contribute to neural diversity.

**Decision letter after peer review:**

Thank you for submitting your article \"Imp/IGF2BP levels modulate individual neural stem cell growth and division through *myc* mRNA stability\" for consideration by *eLife*. Your article has been reviewed by Utpal Banerjee as the Senior Editor, by Claude Desplan as the Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Chris Q Doe (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As you will see, the reviewers are positive about the paper but they together provided a long list of points that could make the paper even better. Below is the extensive list in the three reviews. However, and as it the policy of *eLife*, we would like you to be able to resubmit within a two month period and therefore we have listed below the experiments that we deem essential to improve the paper that could be made in the required time frame. After discussing with the other reviewers, reviewer \#3 took the time to list all required experiments and this was approved by the other reviewers. As for the remaining comments, they only require text modifications/discussion.

Experiments:

\- Stain for *myc (myc* Ab) in WT at 72hour and wandering larval brains

\- UAS-Imp and UAS-Imp RNAi x type 1 Nb Gal4 at wandering stage: Stain for Myc and quantify Myc levels (Myc Ab)

\- UAS-Imp RNAi x type 1 Nb Gal4 at 72hour stage: Stain for Myc

\- Figure 4 -- smFISH against Myc in UAS-Imp x nb Gal4 -- This might take quite some time, but it would clarify the inconsistencies between the different genotypes. However, you might be able to argue your case if you feel that it is not essential

Data analysis:

\- Correlation analysis of smFISH of type 1 NBs done separately from MB NBs. The same correlation analysis could be done for MBs.

\- Figure 6F -- show NB size in this graph to see whether there is correlation between *myc*/imp and cell size at the individual NB level. You might have the data already.

\- Measure Myc levels and NB size from the *Imp* RNAi experiment:

UASImp RNAi x type 1 nbGal4 in 72hour ALH

\- You should also remove the smFISH.

*Reviewer \#1:*

This manuscript makes the following conclusions:

\- Imp promotes NB size and rate of division

\- Imp binds *myc* mRNA

\- Imp binding stablizes *myc* mRNA

\- Imp acts via *myc* to promote NB size and rate of division

\- leading to a final model: Imp post-transcriptionally regulates *myc* mRNA stability to fine-tune individual NB size and division rate in their appropriate developmental context.

Overall the manuscript is clearly written with the data supporting the conclusions. The figures are also clear and illustrate the results well. There are no issues with statistics. This is an excellent manuscript.

*Reviewer \#2:*

The *Drosophila* CNS is built upon generation of thousands of neurons and glia by a small population of asymmetrically dividing neural stem cells, called neuroblasts (NBs). The division properties of NBs have to be tightly spatio-temporally controlled to ensure that they each generate the correct repertoire and number of progeny. It is known that extrinsic and intrinsic cues are operating to control NB divisions, although the underlying mechanisms are not fully understood. Recent work has shown that the mRNA binding protein Imp is a key promoter of NB division during development, and that is needs to be silenced by temporal patterning during larval stages to ensure the timely termination of NB divisions during metamorphosis. However, Imp is known to regulate a large number of mRNAs but its mode of action in NBs is not clear. In this manuscript, Samuels and colleagues investigate in more details the role of Imp in NBs during larval stages and perform RIP-seq to identify mRNA targets. One of their top candidates is Myc. Using antibody and smFISH, they demonstrate that Imp promotes Myc expression via the stabilization of an mRNA isoform with a long 3\'UTR. They show that NBs with high levels of Imp correlate with high levels of Myc, larger size and faster divisions. On the ground of other genetic experiments, they conclude that the temporal and spatial regulation of Myc via Imp determines NB growth and division rate during development.

The manuscript is convincing, with beautiful in situs allowing mRNA quantifications in NBs, and the conclusions are well supported by the experimental data. This study provides an additional layer of understanding of how NB intrinsic temporal patterning regulates NB proliferative properties during development. However, I am less convinced about the conceptual advances that it is bringing.

Indeed, in mammals, Myc is a well-known target of Imp/IGF2BP proteins (Noubissi et al., 2006; Noubissi et al., 2010; Doyle et al., 1998 etc) and the molecular mechanisms by which Imp/IGF2BP proteins promote Myc mRNA stabilization have been investigated in great details (Lemm and Ross, 2002; Weidensdorfer et al., 2009; Huang et al., 2018 etc).

Moreover, Imp/IGF2BP genes are known to be expressed in early cortical progenitors in mice where they promote their proliferation during embryonic development (Nishino et al., 2013; Yang et al., 2015), regulating temporal changes in stem cell properties, as it does in *Drosophila* NBs (Yang et al., 2017). And obviously Myc is famous for promoting cell growth and proliferation. Although the link between Imp/IGF2BPs and Myc had not been described in neural progenitors to my knowledge, this was kind of expected given the known regulatory interactions between these two genes in other tissues and cancers.

*Reviewer \#3:*

In this manuscript the authors address by which molecular mechanism Imp and Syp regulate neuroblast growth and division restraining it or promoting it in different temporal windows. With this goal, the authors show that Imp/Syp levels are important regulators of neuroblast area and division rate. To understand how Imp regulates neuroblast size/division the authors perform RIPseq of Imp::GFP and find Myc RNA as a binding target of Imp in the brain. The authors also show that in the brain Imp binds myc longer isoform 3\' UTR. The authors then want to analyze how Imp affects the stability of Myc mRNA. The authors show that at an earlier larval stage when Imp is more highly expressed, myc\'s half-life is increased, showing that during larval development there is a correlation between Imp levels and Myc half-life. Consistently they also show that in early larval stages/Imp-high neuroblasts are bigger than in wl3. Summing up the authors find evidence for a model where Imp binds and stabilizes Myc mRNA stabilizing it. Since Imp is temporally expressed, being high in earlier larval stages and low/absent in later larval stages, this could explain how this temporal gene regulates neuroblast size in different stages.

This work and final model are very interesting, however, there are several caveats in this work that need to be addressed. These caveats are mainly due to the inconsistencies of the genotypes used to increase or lower Imp levels. Although the authors have tools to directly increase Imp (UAS-Imp) or decrease Imp (Imp-RNAi) they mainly choose to analyse Syp-RNAi and *Imp* RNAi\_*Syp* RNAi. Since, as the authors show and partially discuss, Syp seems to have additional functions other than repressing Imp, and therefore not all the conclusions drawn from these experiments can be taken. Bellow I point out figures/text sections where this occurs. Also, there are some characterizations missing regarding Imp and Myc levels in early vs. late larval stages. These are important and will greatly improve the work, since this will show that levels of Imp/Myc are indeed normally changing in different temporal windows and are therefore relevant in the wild-type developing brain.

Additionally, the authors make several claims, including in the Title of the manuscript that they found how growth and division of individual neuroblasts is regulated, however they in fact study how *imp/syp* regulate growth of type 1 neuroblasts as a group and make some comparisons to another group of neuroblasts, the mushroom body neuroblasts. The experiments showing Imp levels in individual neuroblasts, are well documented and very interesting, but they are not followed up, and in their current state they show no causality between individual levels of Imp and any phenotype. Therefore, all these \"individual nbs\" mechanistic claims should be removed, specially from the Title and Abstract.

Essential revisions:

Figure 1 and Figure 1---figure supplement 1

Figure 1---figure supplement 1:

Figure 1---figure supplement 1B -- Upregulation of Imp in *Syp* RNAi not clear from image, also it is not quantified. From this image *Syp* RNAi does not seem to be upregulating Imp.

In WT -- Imp staining pattern is at the NB membrane (not clear why it would be in glia -- need to either show that these are from glia or tone it down) and in differentiated cells; in *Syp* RNAi -- Imp levels seem to be overall decreased, but there seems to be more Imp at the NB cytoplasm; In Imp OE -- which should be the same as *Syp* RNAi, Imp is again at the neuroblast membrane and in differentiated cells, but it does not show the same pattern as in *Syp* RNAi.

The authors say that *Syp* RNAi causes an increase in Imp cytoplasmic levels and imply that is the important pool of protein. However, although Imp OE does not cause an accumulation of Imp in the NB cytoplasm, ImpOE does cause a NB phenotype (Figure 1A\'B\'). So why the difference? The authors should use ImpOE directly and avoid unspecific effects caused by *Syp* RNAi as shown later on.

Figure 1---figure supplement 1A -- Show levels of Imp with the antibody as in Figure 1---figure supplement 1A but for 72hour larvae. This is important for two reasons: (a) Imp is reported to be almost gone at 72hour larvae in type 1 neuroblasts and to be completely gone by W3IL (van den Ameele and Brand, 2019); (b) so that we can later assess if Myc levels at these two stages are indeed correlated with Imp levels. Without this comparison it is not possible to classify Imp and Myc levels as high or low.

Figure 3 and Figure 4

For the section where the authors explore the relationship of Imp/Myc, the authors do not always directly change Imp levels. In Figure 3 \"Imp regulates Myc protein expression...\" the authors never manipulate Imp directly (ImpOE or *Imp* RNAi), mainly showing how Myc is affected after changing the levels of Syp (*Syp* RNAi as a proxy for Imp overexpression). There are several issues with this approach, since, as discussed by the authors (Figure 4), *Syp* RNAi may cause other effects than on Imp. It would therefore be important to include in figures/results how directly changing Imp levels affects Myc.

Figure 3 -- Show how Imp overexpression affects *myc* protein levels (e.g. as in graph in Figure 1A\' where authors show that ImpOE causes an increase in nb area).

Figure 3 -- Based on the results of Figure 4, where *Imp* RNAi\_*Syp* RNAi does not cause a reduction in Myc Half-life and mature mRNA (i.e. *myc* long isoform stability) as is the case for *Imp* RNAi, but instead possibly causes a decrease in transcription, it would be useful to see *Imp* RNAi and ImpOE effect on *myc* protein levels.

Figure 4 -- The effect of *Imp* RNAi\_*Syp* RNAi on *myc*/transcription is not consistent with this double RNAi being the same as knocking down Imp. It suggests that *Syp* RNAi has an effect independent of Imp. The authors conclusion that the result of this double KD shows \"that Imp rather than Syp is the primary regulator of the number of *myc^long^*\...\" is therefore not supported by the data and needs to be toned down. For this reason, it would also be useful to have ImpOE. Add which developmental stage these analyses were done to the legend.

Figure 4H -- \"we find that Imp\'s main direct role is to promote *myc^long^* mRNA stability and this results in upregulation of Myc protein, which promotes NB growth and division\" however myc half-life is not reduced in *Imp* RNAi, nor in *Imp* RNAi\_*Syp* RNAi, but NB size and division rate is reduced in both genotypes (Figure 1A\'B\'). The authors need to reformulate their conclusion and discuss these inconsistencies.

Figure 5

In Figure 5F authors show Imp levels and *myc* half-life. The authors claim in several sections, including in Title and Abstract, that \"Imp/IGF2BP levels modulate individual neural stem cell growth...\" however the authors do not show this in individual type 1 nbs or show any causality or even correlation. Just by looking at 5F there seems to be no correlation between Imp levels and nb area. Comparison between type 1 central brain and MB is interesting, but these are different cell types, and as shown previously, regulated differently. Therefore these 2 cell types combined cannot be used to conclude what the authors claim. The authors need to: (a) remove individual cell claims, (b) perform a correlation analysis of myc half-life/IMP levels/nb size in only type 1 nbs, the focus of this work.

Figure 5H -Even when type 1 NBs are overexpressing Myc (Figure 3E) they do not reach the average number of progeny labeled as for MB (mycOE type1\~4 progeny cells labeled in 4 hours; MB NBs \~6 progeny cells labeled in 4 hours). Therefore, it does not seem that Myc levels are the main cause of this difference. The authors need to rephrase their conclusions when comparing type1 and MB neuroblasts, since these two nb types seem to have many other differences.

Include in figure legend (check all legends) what is the exact stage analysed.

Figure 6

In Figure 6 the authors try to address how the differential expression of Imp/Syp throughout time affect myc levels and neuroblasts. They find that at 72hour ALH, Imp::GFP levels are high in nbs and in differentiated cells, but at wandering L3 Imp::GFP levels are much reduced, and that this reduction correlates with a decrease in neuroblast area and myc half-life. However, the authors do not show protein levels of Myc (Myc staining) in these 2 stages, this should be included.

The authors should also knock down Imp in 72hour ALH, the stage where Imp is high, and therefore normally playing a role, and see how this affects Myc protein levels.

Figure 6F -- show NB size too in this graph -- to see if indeed there is correlation between myc/imp and cell size at the individual nb level.

Figure 7 -- The insulin signaling or brain sparing is not connected with the process that the authors are studying, i.e. normal temporal regulation of neuroblasts. Remove from this figure as it is confusing. The \"individual intrinsic control\" is also not clear or supported by the data, remove.

Title

The authors are interested in understanding how Imp levels modulates individual neural stem cell growth, however the authors study in general type 1 neuroblasts and do not perform experiments to study how the growth of individual neuroblasts is regulated by Imp. There is one experiment (5F) that characterizes myc half-life, Imp levels and NB area in single neuroblasts, but this experiment does not show if there is correlation among type 1 nbs nor does it show if a difference in levels among type 1 nbs is causal of differences in neuroblast size. For these reasons the Title does not fit with what is really shown in the manuscript, which is how mechanistically Imp levels modulate neuroblast (type 1) growth and division through myc mRNA stability. This needs to be changed.

Abstract

The Abstract should also be adjusted to not highlight differences between individual neuroblasts. E.g. \"mechanisms that control the characteristic proliferation rates of individual neural stem cells are unknown\" -- although correct, this is not what the authors address in their manuscript.

The authors say that \"the division of neural stem cells, regulated systemically by known extrinsic signals.\" -- \"Some\", or \"Important\" extrinsic signals are known.

Graphical abstract:

The graphical abstract should be adjusted according to comments above.

10.7554/eLife.51529.sa2

Author response

> As you will see, the reviewers are positive about the paper but they together provided a long list of points that could make the paper even better. Below is the extensive list in the three reviews. However, and as it the policy of eLife, we would like you to be able to resubmit within a two month period and therefore we have listed below the experiments that we deem essential to improve the paper that could be made in the required time frame. After discussing with the other reviewers, reviewer \#3 took the time to list all required experiments and this was approved by the other reviewers. As for the remaining comments, they only require text modifications/discussion.

We thank the reviewers and editors for distilling the essential points we need to address and agree that these changes have improved the paper considerably. In our revision we have focused on addressing the distilled points, but we have also attempted to address all the other comments, as in our view they also improve the manuscript.

> Experiments:
>
> \- Stain for myc (myc Ab) in WT at 72hour and wandering larval brains.

While we show Myc antibody staining in wandering larval brains in Figure 3A, we have been unable to reproducibly stain 72 hour larval brains with the Myc antibody. We have tried hard to carry out this experiment, both before and after receiving these review comments, by testing different fixing protocols (including methanol fixing and 1% or 4% formaldehyde) as well as different Myc antibody concentrations and pre-clearing the antibody. While some of our stainings indicate that Myc protein is quite highly expressed in 72 hour type I NBs, we are not comfortable to publish these data because the stainings are not reproducible and so can not be validly quantitated. Nevertheless, we do show in Figure 6 that NBs are larger at 72 hour compared to wL3 and that *myc* mRNA half-life is increased. Although we agree that the Myc staining would have been a nice addition, we do not think that it is essential to our argument that higher Imp at 72 hour results in increased *myc* mRNA stability, which we measure directly. We have added a short statement to the Materials and methods section saying that the Myc antibody does not work in our hands in 72 hour larvae.

> \- UAS-Imp and UAS-Imp RNAi x type 1 Nb Gal4 at wandering stage: Stain for Myc and quantify Myc levels (Myc Ab).

This was a very useful suggestion, thank you. The results have also helped us to address some of the additional specific comments raised by the reviewers. We have added measurements of Myc protein levels in the UAS-Imp and *Imp* RNAi lines to Figure 3C. The results show a small increase in Myc protein when Imp is overexpressed (OE). This effect is expected, as only a small Imp OE can be achieved with this construct (Figure 1 -- ---figure supplement 1D), as previously observed by Tzumin Lee's lab (Liu et al., 2015; Yang et al., 2017). In the *Imp* RNAi, we observe only a small, reduction in Myc protein. This result is also expected because Imp levels are already very low in the *wild type* at wL3. These findings support our interpretation that Imp stabilises *myc* mRNA to determine Myc protein levels in the type I NBs, which in turn determine their rate of division and growth.

> \- UAS-Imp RNAi x type 1 Nb Gal4 at 72hour stage: Stain for Myc.

As addressed above, we have been unable to get reproducible specific Myc antibody staining at 72 hour ALH. However, we have knocked down Imp in type I NBs at 72 hour and instead measured NB size, showing that NBs are much smaller in the *Imp* RNAi, compared to the *wild type* at this stage (Figure 6F). Note that at the 72 hour Imp levels are high (compared with the very low third instar Imp levels described above, Figure 6A), explaining why the *Imp* RNA has large effect at the earlier stage. Again, these findings agree with our interpretation, namely that Imp promotes increased NB growth through stabilising *myc* mRNA.

> \- Figure 4 -- smFISH against Myc in UAS-Imp x nb Gal4 -- This might take quite some time, but it would clarify the inconsistencies between the different genotypes. However, you might be able to argue your case if you feel that it is not essential.

As described above, overexpression of Imp from a UAS construct results in minimal upregulation of Imp protein in the NB, and we now show that using the Imp OE construct we only see a small increase in Myc protein (Figure 3C). In response to the above comment, we have stained UAS-Imp brains with smFISH against *myc* mRNA (Figure 4---figure supplement 1B), but we do not observe a substantial upregulation of *myc* mRNA, especially compared to the increase seen with *Syp* RNAi. We think that quantitations of *myc* half-life and transcription rate in the Imp OE genotype will be much less useful than our studies using the *Syp* knockdown, which produces a very large upregulation of Imp protein in the NB and a corresponding large upregulation of Myc protein.

> Data analysis:
>
> \- Correlation analysis of smFISH of type 1 NBs done separately from MB NBs. The same correlation analysis could be done for MBs.

Based on reviewer 3's comment below, we think this comment is referring to Figure 5F in which we plot *myc* mRNA half-life verses Imp levels and NB size for all the NBs. These data are also plotted in bulk in Figure 5B-E, but we show the individual NBs in a single graph in 5F to illustrate more clearly the differences between NB types. Identifying the different cell types to clearly separate the type I NBs and MB NBs is a very good suggestion. We have addressed this by adjusting the graph in Figure 5F to mark the type I NBs with a diamond and MB NBs with a circle, in order to clearly emphasise the differences between the NB types.

The reviewer also asks us to show do separate correlation analysis in each of the two different classes of NBs. However, we think that doing so would not be very informative for type I NBs because the at wL3, Imp levels in *wild type* type I NBs are very low (at the detection threshold). Therefore, we don't think it is informative to look for correlations between Imp level (always very low) and *myc* mRNA stability in type I NBs at the wL3 stage. However, we did correlation analysis for MB NBs at wL3 using the data shown in Figure 5F, which is potentially useful as the MB NBs express higher Imp levels and there is variability between individual MB NBs. Although we have only very limited cell numbers for this type of analysis, we find that Imp level significantly correlates with *myc* transcript number (r = 0.48, p = 0.015). There is also a positive correlation between Imp level and *myc* mRNA half-life but this is not statistically significant (r = 0.29, p = 0.18). We have not gathered additional data for more individual MB NBs in this experiment in order to add it to the paper, as it would be very time consuming and we don't think it is essential for the conclusions of the paper, which primarily focuses on type I NBs. In any case, we do already show in the paper the correlation analysis for type I NBs at stage 72 hour (Figure 6G, Figure 6---figure supplement 1), when there is much larger variation in Imp levels between individual type I NBs. We feel the data showing correlations in Figure 6 is strong and is sufficient for us to make our conclusions on individual NBs.

> \- Figure 6F -- show NB size in this graph to see whether there is correlation between myc/imp and cell size at the individual NB level. You might have the data already.

The reviewer is correct: we do have all the data they are asking for, which is displayed in Figure 6---figure supplement 1 including all the correlation values and significance. We have measured 5 distinct variables, so we feel that it is better to represent them in a table showing a correlation matrix than to show plots of all the possible combinations. The reason we chose to show the one graph we did is that the correlation between Imp protein levels and *myc* mRNA stability in individual NBs is the key subject of this paper. Regarding the requested specific correlations between NB size and Imp/*myc*, we show in Figure 6---figure supplement 1, that *myc* transcript number does correlate with NB size, but Imp level does not correlate with NB size. We highlight this result in the corresponding Results section, and also discuss the reasons in the Discussion section. Cell size may be a poor proxy for cell growth at the early larval stage of 72hour ALH, when NB sizes are rapidly changing and we suggest in the Discussion section that long-term live imaging with Imp measurement could provide a better quantitation of cell growth.

> \- measure Myc levels and NB size from the Imp RNAi experiment:
>
> UASImp RNAi x type 1 nbGal4 in 72hour ALH.

In response to the above comment, we have measured NB size in the *Imp* RNAi at 72 hour ALH, and found that NBs are much smaller in the *Imp* RNAi, compared to the *wild type* at this stage (Figure 6F). This is a useful addition to the paper as it confirms that Imp drives NB growth at the earlier 72 hour stage, as well as at wL3 (Figure 1A, A'). As explained above, we were unable to produce Myc antibody staining at 72 hour ALH.

> Reviewer \#2:
>
> \[...\] The manuscript is convincing, with beautiful in situs allowing mRNA quantifications in NBs, and the conclusions are well supported by the experimental data. This study provides an additional layer of understanding of how NB intrinsic temporal patterning regulates NB proliferative properties during development. However, I am less convinced about the conceptual advances that it is bringing.
>
> Indeed, in mammals, Myc is a well-known target of Imp/IGF2BP proteins (Noubissi et al., 2006; Noubissi et al., 2010; Doyle et al., 1998 etc) and the molecular mechanisms by which Imp/IGF2BP proteins promote Myc mRNA stabilization have been investigated in great details (Lemm and Ross, 2002; Weidensdorfer et al., 2009; Huang et al., 2018 etc).
>
> Moreover, Imp/IGF2BP genes are known to be expressed in early cortical progenitors in mice where they promote their proliferation during embryonic development (Nishino et al., 2013; Yang et al., 2015), regulating temporal changes in stem cell properties, as it does in *Drosophila* NBs (Yang et al., 2017). And obviously Myc is famous for promoting cell growth and proliferation. Although the link between Imp/IGF2BPs and Myc had not been described in neural progenitors to my knowledge, this was kind of expected given the known regulatory interactions between these two genes in other tissues and cancers.

While it is true that in mammals the relationship between Myc and Imp has been previously studied, our imaging approach provides a major conceptual advance. We measure *myc* regulation in single cells within the developing brain to uncover how Imp regulates Myc to regulate individual neural stem cell size and division rate. Finally, in the Discussion section of the manuscript we address this point directly and reference much of the above mammalian literature.

> Reviewer \#3:
>
> \[...\] This work and final model are very interesting, however, there are several caveats in this work that need to be addressed. These caveats are mainly due to the inconsistencies of the genotypes used to increase or lower Imp levels. Although the authors have tools to directly increase Imp (UAS-Imp) or decrease Imp (Imp-RNAi) they mainly choose to analyse Syp-RNAi and Imp RNAi_Syp RNAi. Since, as the authors show and partially discuss, Syp seems to have additional functions other than repressing Imp, and therefore not all the conclusions drawn from these experiments can be taken. Bellow I point out figures/text sections where this occurs.

(Many of these points have been addressed in more depth above in our responses to the distilled list from the reviewers)

We have expanded on these points below, where they are individually raised, but briefly: we primarily use the *Syp* RNAi to upregulate Imp because the effect is much greater than using the UAS construct to directly overexpress Imp. We have added the experiments suggested by reviewer 3, measuring Myc protein level in the UAS-Imp and *Imp* RNAi brains, and find small changes in Myc level, as we would predict. This result is a useful addition to the paper, supporting our model. However, it remains the case, that the larger Imp upregulation in the *Syp* RNAi brains is a better system for us to detect changes in *myc* mRNA stability using smFISH.

> Also, there are some characterizations missing regarding Imp and Myc levels in early vs. late larval stages. These are important and will greatly improve the work, since this will show that levels of Imp/Myc are indeed normally changing in different temporal windows and are therefore relevant in the wild-type developing brain.

We have measured Imp level in 72 hour and wL3 NBs and show that Imp level decreases in the NB over this developmental time period. However, despite trying hard, we have not been able to optimise the Myc antibody for staining 72 hour ALH brains and so unfortunately, we have not been able to compare Myc level at 72 hour and wL3. Although this was a relevant and useful suggestion, we do not think this experiment is essential for our conclusions that Imp promotes *myc* mRNA stability.

> Additionally, the authors make several claims, including in the Title of the manuscript that they found how growth and division of individual neuroblasts is regulated, however they in fact study how imp/syp regulate growth of type 1 neuroblasts as a group and make some comparisons to another group of neuroblasts, the mushroom body neuroblasts. The experiments showing Imp levels in individual neuroblasts, are well documented and very interesting, but they are not followed up, and in their current state they show no causality between individual levels of Imp and any phenotype. Therefore, all these \"individual nbs\" mechanistic claims should be removed, specially from the Title and Abstract.

The reviewer is correct that for the first part of the paper we study type I NBs at wL3 as a group, as this is a good system to measure the effects of experimental manipulations of Imp level. We then compare type I NBs to mushroom body NBs, which have a higher Imp level at the same wL3 stage. However, at the end of the paper we measure Imp level, *myc* mRNA stability and NB size in individual type I NBs at 72 hour ALH (Figure 6G and Figure 6---figure supplement 1). At this stage there is heterogeneous Imp expression between individual type I NBs and so this is the ideal system to test the effect of different Imp levels in individual NBs. We find a significant positive correlation between Imp levels and *myc* mRNA stability in individual type I NBs at 72 hour ALH. Collectively, we feel that we have provided good evidence to support our model that Imp stabilises *myc* mRNA in individual NBs.

> Essential revisions:
>
> Figure 1 and Figure 1---figure supplement 1
>
> Figure 1---figure supplement 1:
>
> Figure 1---figure supplement 1B -- Upregulation of Imp in Syp RNAi not clear from image, also it is not quantified. From this image Syp RNAi does not seem to be upregulating Imp.

We have updated Figure 1---figure supplement 1 by zooming closer to the NBs to show the upregulation of Imp in the *Syp* RNAi. We also indicated a single type I NB in each image with an arrow. We feel it should be much easier for the reader to now see the upregulation of Imp.

> In WT -- Imp staining pattern is at the NB membrane (not clear why it would be in glia -- need to either show that these are from glia or tone it down) and in differentiated cells; in Syp RNAi -- Imp levels seem to be overall decreased, but there seems to be more Imp at the NB cytoplasm; In Imp OE -- which should be the same as Syp RNAi, Imp is again at the neuroblast membrane and in differentiated cells, but it does not show the same pattern as in Syp RNAi.

To address this comment, we have stained a glial GAL4 (nrv2-GAL4) driving mCD9::GFP with Imp antibody and showed that Imp is expressed in glial cells. However, it is not directly relevant to the paper, so we have not included these data and instead altered the wording in the legend of Figure 1---figure supplement 1 to tone down the suggestion that Imp is expressed in glia. We agree with the reviewer's observation that there is a reduction in Imp levels in many neurons in the *Syp* RNAi. However, we are measuring changes in only the NB where, as the reviewer observes, Imp is upregulated in the cytoplasm. The Imp OE is not very effective at upregulating Imp in the NB (described extensively above) and we agree that the greatest effect is in the neurons. For this reason, we primarily use the *Syp* RNAi to 'upregulate' Imp in the NB.

> The authors say that Syp RNAi causes an increase in Imp cytoplasmic levels and imply that is the important pool of protein. However, although Imp OE does not cause an accumulation of Imp in the NB cytoplasm, ImpOE does cause a NB phenotype (Figure 1A\'B\'). So why the difference? The authors should use ImpOE directly and avoid unspecific effects caused by Syp RNAi as shown later on.

We agree that it would be cleaner to use the Imp OE directly. However, in agreement with previously published work, we find expressing Imp from an overexpression construct in NBs has minimal effect on Imp expression at wL3 (Liu et al., 2015; Yang et al., 2017) (Figure 1---figure supplement 1D). The Imp upregulation is much more dramatic in the *Syp* RNAi line and therefore we use the *Syp* RNAi line to upregulate Imp for the purposes of the smFISH quantitation (explanation added to subsection "Myc expression is regulated by Imp levels"). Nevertheless, we measured Myc protein expression in the Imp overexpression construct as suggested by the reviewer below, and we found a small increase in Myc protein levels in the NB. This small increase in Myc protein may be sufficient to explain the phenotypes that we see in the Imp OE in Figure 1.

> Figure 1---figure supplement 1A -- Show levels of Imp with the antibody as in Figure 1---figure supplement 1A but for 72hour larvae. This is important for two reasons: (a) Imp is reported to be almost gone at 72hour larvae in type 1 neuroblasts and to be completely gone by W3IL (van den Ameele and Brand, 2019); (b) so that we can later assess if Myc levels at these two stages are indeed correlated with Imp levels. Without this comparison it is not possible to classify Imp and Myc levels as high or low.

We show and measure the levels of Imp in 72 hour larvae and wL3 larvae in Figure 6A and 6B with the *Imp::GFP* line. In our hands in the *Imp::GFP* genotype, there is reproducibly Imp protein remaining at 72 hour ALH, and this is lost (below detection threshold) by wL3.

> Figure 3 and Figure 4
>
> For the section where the authors explore the relationship of Imp/Myc, the authors do not always directly change Imp levels. In Figure 3 \"Imp regulates Myc protein expression...\" the authors never manipulate Imp directly (ImpOE or Imp RNAi), mainly showing how Myc is affected after changing the levels of Syp (Syp RNAi as a proxy for Imp overexpression). There are several issues with this approach, since, as discussed by the authors (Figure 4), Syp RNAi may cause other effects than on Imp. It would therefore be important to include in figures/results how directly changing Imp levels affects Myc.
>
> Figure 3 -- Show how Imp overexpression affects myc protein levels (e.g. as in graph in Figure 1A\' where authors show that ImpOE causes an increase in nb area).
>
> Figure 3 -- Based on the results of Figure 4, where Imp RNAi_Syp RNAi does not cause a reduction in Myc Half-life and mature mRNA (i.e. myc long isoform stability) as is the case for Imp RNAi, but instead possibly causes a decrease in transcription, it would be useful to see Imp RNAi and ImpOE effect on myc protein levels.

Collectively, these comments ask for quantitations of Myc protein in the *Imp* RNAi and *Imp* OE type I NBs at wL3. This was a very useful suggestion, discussed fully above in the main response. Briefly, we have added the requested quantitations of Myc protein levels in the UAS-Imp and UAS-*Imp RNAi* lines at the wandering stage in Figure 3C, referred to in subsection "Imp binds hundreds of mRNA targets in the brain, including *myc*". We find a small increase in Myc protein in the UAS-Imp NBs, which corresponds to the minimal upregulation of Imp in the Imp overexpression constructs (Figure 1---figure supplement 1D). We also find a small decrease in Myc protein in the *Imp* RNAi NBs, which is again expected because Imp levels are already very low in *wild type* type I NBs at wL3, and therefore *Imp* knockdown would not have a large additional effect. These results support our model that Imp upregulates Myc protein, but the changes are small due to the small changes in Imp level with the OE and RNAi constructs at the wL3 stage.

> Figure 4 -- The effect of Imp RNAi, Syp RNAi on myc/transcription is not consistent with this double RNAi being the same as knocking down Imp. It suggests that Syp RNAi has an effect independent of Imp. The authors' conclusion that the result of this double KD shows \"that Imp rather than Syp is the primary regulator of the number of myc^long^.\" is therefore not supported by the data and needs to be toned down. For this reason, it would also be useful to have ImpOE. Add stage these analyses were done to the legend.

As discussed more extensively above, Imp overexpression with the UAS Imp construct only has a small effect on Imp protein level, compared to the much greater upregulation with the *Syp* RNAi. To address this comment, we have added *myc* smFISH in the Imp OE to Figure 4---figure supplement 1B, but we don't think it is useful to do extensive quantitations with the Imp OE. We have also added details of the developmental stage to each figure legend.

> Figure 4H -- \"we find that Imp\'s main direct role is to promote myc^long^ mRNA stability and this results in upregulation of Myc protein, which promotes NB growth and division\" however myc half-life is not reduced in Imp RNAi, nor in Imp RNAi_Syp RNAi, but NB size and division rate is reduced in both genotypes (Figure 1A\'B\'). The authors need to reformulate their conclusion and discuss these inconsistencies.

The reviewer is asking why we see a phenotype in the *Imp* RNAi, but no significant change in *myc* mRNA stability compared to *wild type*. At the wL3 stage, Imp is very low in the *wild type* type I NBs, and therefore knocking down Imp would not be expected to have a very large effect. In the *Imp* RNAi we observe a small but significant decrease in Myc protein (added to Figure 3C) as well as a small but not significant reduction in *myc* mRNA half-life to 0.6-fold of *wild type myc* half-life. This small reduction in Myc expression in the *Imp* RNAi NBs may be sufficient to explain the phenotype of smaller, slower dividing NBs. There may also be an additional effect of Imp-depletion throughout larval development i.e. reduced Imp level leading to less NB growth in early larval stages might be expected to result in smaller NBs at wL3.

> Figure 5
>
> In Figure 5F authors show Imp levels and myc half-life. The authors claim in several sections, including in Title and Abstract, that \"Imp/IGF2BP levels modulate individual neural stem cell growth...\" however the authors do not show this in individual type 1 nbs or show any causality or even correlation. Just by looking at 5F there seems to be no correlation between Imp levels and nb area. Comparison between type 1 central brain and MB is interesting, but these are different cell types, and as shown previously, regulated differently. Therefore these 2 cell types combined cannot be used to conclude what the authors claim. The authors need to (a) remove individual cell claims, (b) perform a correlation analysis of myc half-life/IMP levels/nb size in only type 1 nbs, the focus of this work.

The reviewer is correct that in Figure 5 we do not carry out correlation analysis between individual type I NBs and mushroom body NBs at wL3. This point is addressed more fully above, but briefly, we do not think it would be useful to do correlation analysis on type I NBs at wL3 because Imp level is very low in all type I NBs at this stage. Instead, our conclusions on individual NBs are drawn from Figure 6 and Figure 6---figure supplement, using measurements of individual type I NBs at 72 hour ALH. At 72 hour ALH, there is heterogeneous Imp expression, which allows us to examine the effect on different levels of Imp on *myc* mRNA stability and NB behaviour.

We use Figure 5 to draw conclusions between the differences between type I NBs (low Imp) and mushroom body NBs (high Imp). To highlight this difference, we have adjusted the graph in Figure 5F to distinguish the NB types (type I NB with a diamond, MB NB with a circle) in order to clearly emphasise the differences between the NB types.

> Figure 5H -Even when type 1 NBs are overexpressing Myc (Figure 3E) they do not reach the average number of progeny labeled as for MB (mycOE type1\~4 progeny cells labeled in 4 hours; MB NBs \~6 progeny cells labeled in 4 hours). Therefore, it does not seem that Myc levels are the main cause of this difference. The authors need to rephrase their conclusions when comparing type1 and MB neuroblasts, since these two nb types seem to have many other differences.

This is an interesting observation, but we aren't confident that our Myc OE is directly equivalent to the high Myc levels in MB NBs. Furthermore, the changing levels of Myc throughout larval development may have some continued effect at the wL3 stage. Nevertheless, to address this comment we have added to our discussion other differences between MB NBs and type I NBs in subsection "Regulated Imp levels control *myc* mRNA 447 stability in individual NBs and NB types\".

> Include in figure legend (check all legends) what is the exact stage analysed.

Added.

> Figure 6
>
> In Figure 6 the authors try to address how the differential expression of Imp/Syp throughout time affect myc levels and neuroblasts. They find that at 72hour ALH, Imp::GFP levels are high in nbs and in differentiated cells, but at wandering L3 Imp::GFP levels are much reduced, and that this reduction correlates with a decrease in neuroblast area and myc half-life. However, the authors do not show protein levels of Myc (Myc staining) in these 2 stages, this should be included.
>
> The authors should also knock down Imp in 72hour ALH, the stage where Imp is high, and therefore normally playing a role, and see how this affects Myc protein levels.

These suggestions are addressed thoroughly above, briefly we have tested different fixing protocols (methanol fixing and 1% or 4% formaldehyde) as well as different Myc antibody concentrations, but are unable to satisfactorily optimise the Myc antibody staining at 72 hour ALH to perform these experiments. Although this would be a useful addition, we don't think the Myc antibody staining is essential to support our conclusion that Imp stabilises *myc* mRNA, which we measure directly.

> Figure 6F -- show NB size too in this graph -- to see if indeed there is correlation between myc/imp and cell size at the individual nb level.

This suggestion is discussed fully in the main response. Briefly, the correlation matrix for all five variables is found in Figure 6---figure supplement 1. We have chosen not to add NB size into the Figure 6F (now Figure 6G) graph as we want to focus on the main conclusion that Imp stabilises *myc* mRNA in individual NBs. Referring to the specific correlation requested, we find that *myc* transcript number does correlate with NB size, but Imp level does not correlate with NB size. We highlight this fact in the corresponding Results section, and also discuss the reasons in the Discussion section.

> Figure 7 -- The insulin signaling or brain sparing is not connected with the process that the authors are studying, i.e. normal temporal regulation of neuroblasts. Remove from this figure as it is confusing. The \"individual intrinsic control\" is also not clear or supported by the data, remove.

This is a good point, we have added a question mark to the systemic extrinsic signals in Figure 7A and added to the text of the figure legend, to clarify that although this is a plausible model, it has not been directly addressed in the type I NBs.

> Title
>
> The authors are interested in understanding how Imp levels modulates individual neural stem cell growth, however the authors study in general type 1 neuroblasts and do not perform experiments to study how the growth of individual neuroblasts is regulated by Imp. There is one experiment (5F) that characterizes myc half-life, Imp levels and NB area in single neuroblasts, but this experiment does not show if there is correlation among type 1 nbs nor does it show if a difference in levels among type 1 nbs is causal of differences in neuroblast size. For these reasons the Title does not fit with what is really shown in the manuscript, which is how mechanistically Imp levels modulate neuroblast (type 1) growth and division through myc mRNA stability. This needs to be changed.

This is not quite correct, we show experiments in both Figure 5 and Figure 6 measuring *myc* half-life, Imp levels and NB area in individual NBs. We make our conclusions on the role of differing levels of Imp in individual NBs from the data shown in Figure 6 and Figure 6---figure supplement 1. At 72 hour ALH we observed heterogenous Imp expression in type I NBs, and we use this system to show that Imp level is positively correlated with *myc* mRNA stability in individual NBs. In Figure 5F, we make individual NB measurements but do not use these for correlation analysis because the levels of Imp in the type I NBs are always very low in each cell at wL3.
